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Background: Tuberculosis (TB) is a major global health problem. About 15-20% of the 
global population who are HIV negative have extra-pulmonary TB (EPTB) such as pleural 
TB. This increases to 50-70% in HIV positive people. The diagnosis of EPTB is challenging 
because of the low bacillary burden. Interferon gamma (IFN-γ) has been identified as a 
promising biomarker for the diagnosis of EPTB. The development of rapid and accurate 
point-of-care (POC) diagnostic technologies becomes crucial in controlling EPTB. Aptamers 
referred to as “synthetic antibodies” have been recently explored as a replacement for 
antibodies in diagnostic platforms. These single-stranded nucleic acid molecules have high 
affinity and specificity comparable, and in some instances even superior, to those of 
antibodies; in addition to their relatively low cost and simple method of production they have 
the potential to reduce assay turnaround time.   
Aim: The aim of this thesis was to develop aptamers to IFN-γ, a biomarker specific for 
EPTB, thus facilitating the development of aptamer-based POC tests for the diagnosis of 
EPTB. 
Methods: Single-stranded DNA aptamers were selected against IFN-γ using the Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX) protocol. Eight rounds of 
selection were performed.  Enrichment of the recovered RNA that bound IFN-γ reached 50% 
and plateaued at round 6. Therefore DNA pool recovered from round 6 was cloned and 
sequenced. Binding studies were performed using enzyme-linked oligonucleotide assay 
(ELONA), Biacore™ surface plasmon resonance (SPR) technology and bioinformatics, 
respectively.  
Results: 41 of the 60 (68%) aptamers screened significantly bound IFN-γ (p≤0.05). 
Homology and phylogenetic analyses revealed 60% shared homology of the aptamers. 
Bioinformatic analysis for secondary structure predictions for the six selected aptamer 
displayed more than two possible structure predictions for each aptamer. Furthermore, 
aptamers A1 and B4 had the ability to form a G-quadruplex. A limit of detection of 10 µg/ml 
(IFN-γ) was determined. A time-course assay showed that aptamers A1, B2 and H12 had no 
difference in binding at 60 min vs.120 min. All six aptamers had an equilibrium dissociation 
constant (KD) in the sub-nanomolar to picomlar range, with aptamers H12 and A9 having the 
lowest at 2.06E-10 (206 pM) and 3.90E-10 (390 pM), respectively. All the aptamers had 
high specificity for IFN-γ when tested against TB-related and unrelated molecules (p≤0.001). 
A competition assay with an anti-IFN-γ antibody, CD66, showed that aptamer H12 did not 




assay. Aptamer A1 was further truncated to yield derivatives, 49mer, 36mer and 29mer. 
When binding affinities of the full length (90mer) was compared to truncated derivatives 
49mer, 36mer and 29mer at OD450, the binding of the 49mer was significantly reduced (OD 
of 49mer = 0.403 vs. 90mer = 0.651 (p≤0.01). 
Conclusion: In this study, I selected at least six aptamers, which bound IFN-γ with high 
affinity and specificity, and have a potential for use in POC diagnostic platforms for EPTB. 
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In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global 
public health emergency. Although the TB epidemic has plateaued in several regions 
of the world, in Africa, fuelled by poverty and HIV co-infection, TB is out of control 
(WHO, 2010). South Africa is facing a TB problem of such magnitude that this 
disease has been declared a national health emergency. To minimize transmission, 
early case detection and subsequent treatment initiation are important. However, the 
development of new TB diagnostic technologies remains a challenge. Thus, a 
number of technologies have been endorsed by the WHO; however, most of these 
still have limitations according to the guidelines set by the organization (WHO, 
2012). The major gap missing in diagnostics is the lack of suitable technologies to 
test existing biomarkers on. The ideal POC test should follow the ASSURED 
guidelines (Mabey et al., 2004)  (Table 1.1). 
 
Table 1.1: ASSURED criteria specifying ideal characteristics of a POC test  
A Affordable 
 




Have high sensitivity 




Simple to perform with no training required 
 
R Robust and rapid 
 
Availability of results in <30 minutes 
 
E Equipment-free Should ideally be battery-operated 
 
D Deliverable to the end-user Should be suitable for use in the field 
 
 
Aptamers, a new promising technology, has been introduced in diagnostics and 
therapeutics (Ellington and Szostak, 1990a) and may have proven to satisfy the 
characteristics of a suitable POC test. These molecules have been successfully used 
in therapeutics as delivery vehicles (Nimjee et al., 2005a, Nimjee et al., 2005b, 
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Rusconi et al., 2002, Keefe et al., 2010) and in the development of diagnostics such 
as aptasensors, aptamer arrays and in sandwich ELISA formats (Drolet et al., 1996, 
Hong et al., 2012, Inoue et al., 2011, Pultar et al., 2009). Aptamers are known for 
their specificity and high binding affinity to their targets (Ellington and Szostak, 
1990a, Eaton et al., 1995) and thus, these characteristics make them attractive as 
molecules of choice for the abovementioned applications. Aptamers for TB 
biomarkers such as ESAT6-CFP10, IFN-γ, MPT64 and EsxG proteins have been 
previously identified (Qin et al., 2009, Rotherham et al., 2012, Ngubane et al., 2014, 
Tang et al., 2014, Lee et al., 1996, Cao et al., 2014). This chapter summarises the 
current knowledge on TB and EPTB with a focus on diagnostics. The gaps and 
potential ways to fill them will be discussed including the use of the aptamer 
technology as an alternative to developing new TB diagnostic tools. This will be 
followed by stating the objectives and aims of this study together with an outline of 
the structure of the thesis. 
 
1.2 TUBERCULOSIS  
1.2.1 Pathogenesis of Mycobacterium Tuberculosis  
Mycobacterium tuberculosis (M.tb) is a causative agent of TB.  It is a slow growing, 
acid fast bacilli whose cell wall structure is very complex compared to its other 
counterparts within the Mycobacterium Tuberculous Complex (MTBC) genus (Lawn 
and Zumla, 2011). Due to its complex cell wall, which is lipid-rich and hence highly 
impermeable, infected patients are required to stay on treatment for periods of up to 
6-9 months (Lawn and Zumla, 2011, Knechel, 2009, Todar, 2008).  M.tb is an 
aerobic bacterium; hence it prefers organs or tissues in the body which are high in 
oxygen, such as lungs. It is transmitted through inhalation of small aerosol droplets 
usually through sneezing, talking or coughing from an infected person. Settling of 
these aerosols in the lungs cause pulmonary tuberculosis (PTB) (Knechel, 2009). 
Should the TB disseminate to other parts of the body, which is likely to occur in 
those with compromised immune systems, such as those with HIV (Sharma et al., 
2005, Raviglione et al., 1992), diabetes (Singla et al., 2006, Martinez and Kornfeld, 
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2014, van Crevel and Dockrell, 2014), the elderly (Negin et al., 2015) and young 
children (Zar et al., 2010, Connell et al., 2011, Madhi et al., 2000, Maltezou et al., 
2000, Marais and Schaaf, 2014), then the disease is termed EPTB (Golden and 
Vikram, 2005).  A simple definition for EPTB would therefore be TB affecting any 
other organ within the body (Figure 1.1) excluding the lungs (WHO, 2014).  
 
 
Figure 1.1: A schematic depicting the main organs of the body affected by extra-pulmonary 
tuberculosis (Häggström, 2009).  
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1.2.2 Tuberculosis Epidemiology  
Tuberculosis accounts globally for 9 million new cases and 1.5 million deaths 
annually (WHO, 2014). This was an annual increase from 8.6 and 1.3 million for 
new cases and deaths, respectively. This mortality rate is unacceptably high given 
that TB is treatable if only people can access health care facilities and receive a 
timely diagnosis (WHO, 2014) resulting in preventable deaths. Children and women 
were the most affected accounting for 550 000 and 3.3 million of the 9 million 
incident cases, respectively. South Africa, India, Indonesia, China, Nigeria and 
Pakistan were countries with the highest incident cases. South Africa reported 
between 410 000 and 520 000 cases in 2013. Of the 1.5 million people who died of 
TB, 1.1 million were HIV-negative and about a quarter were HIV-positive with 
South Africa as one of the countries with the highest proportion of TB cases co-













Figure 1.2: Estimated HIV prevalence in new and relapsed TB cases 2013 (WHO, Global 
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1.3 EXTRA-PULMONARY TUBERCULOSIS 
1.3.1 Prevalence of EPTB 
The African region reported the highest TB cases co-infected with HIV (WHO, 
2014). Many organs can be involved in EPTB. Extra-pulmonary TB has increased 
over the last two decades; it accounted for between 15-20% of all reported TB cases 
(WHO, 2012) (Figure 1.3: A). In sub-Saharan Africa, however, this figure increased 
immensely since the advent of HIV with over 50% of these TB cases being persons 
with TB-HIV co-infection (WHO, 2014). In general, lymph node TB seems to be the 
most common of all EPTB cases accounting for about 35%, followed closely by 
pleural TB at 20% (Figure 1.3: B) (Sharma and Mohan, 2004, Peto et al., 2009). The 
disseminated form of the disease allows some patients to present with both PTB and 
EPTB, especially those co-infected with HIV (Figure 1.3: B). In the absence of HIV, 
lymph node TB is the most common in children under the age of 14 years (Norbis et 
al., 2014). Genitourinary and joint TB cases are mostly seen with increasing age, and 
the elderly are mostly infected with meningeal and miliary TB (Figure 1.3: B) 



















Figure 1.3: Prevalence of PTB vs. EPTB and distribution of EPTB by disease site in HIV-
uninfected individuals.  
(A) Prevalence of PTB and EPTB of all TB cases. PTB accounts for 75% and EPTB 15-20% of all TB 
cases. (B) Distribution of TB by anatomical site in HIV-uninfected patients of the constituted 15-20% 
of all TB cases. PTB-pulmonary TB, EPTB-extra-pulmonary TB (Adapted from Sharma and Mohan, 
2004). 
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1.3.2 Current status of EPTB in sub-Saharan Africa 
People living with HIV are 29 times more likely to contract TB compared to those 
who are HIV-negative, with the worst statistics reported in Southern and Eastern 
Africa (WHO, 2014). In South Africa, the epidemic of HIV/AIDS in the last two 
decades has changed the whole spectrum of TB. In HIV-positive patients, M.tb 
infection tends to be more aggressive, sometimes presenting with both manifestations 
of the disease i.e. PTB and EPTB (WHO, 2013). For this reason, it becomes 
clinically challenging to treat and diagnose (Lee, 2015, Al-Otaibi et al., 2012). In the 
20% of patients estimated to have EPTB and are HIV-positive the majority of them 
are sputum scarce, as is the case in very young children and the elderly (Negin et al., 
2015).  
 
1.4 CURRENT DIAGNOSTIC TOOLS FOR EPTB – A 
CHALLENGE 
Due to EPTB being able to affect almost any organ of the body, the clinical 
specimens for diagnosis are diverse. The type of EPTB a patient might get varies 
with gender, age, ethnicity, geographical area and predisposing risk factors such as 
previous history of TB, high prevalence of TB, HIV and diabetes (Norbis et al., 
2014, Sharma et al., 2005, Martinez and Kornfeld, 2014). Samples from EPTB 
patients tend to be paucibacillary, thus decreasing the sensitivity of diagnostic tests 
(Al-Otaibi et al., 2012, Moure et al., 2012, Harries et al., 1998). Furthermore, some 
specimens (e.g. deep lymph nodes) are sometimes difficult to obtain depending on 
which organ is affected (Golden and Vikram, 2005). In addition, patients with EPTB 
have a wide spectrum of atypical clinical features and often present late in order to 
seek medical attention. This unfortunately leads to late diagnosis and thus delayed 
treatment initiation. This is a danger, especially in patients infected with meningeal 
TB who can die within a few days if not treated (Rock et al., 2008, Golden and 
Vikram, 2005).  According to the WHO, the new regulation for EPTB diagnosis 
should be based on: 
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 One-culture positive specimen, or 
 Positive histology, or 
 Strong clinical evidence consistent with active EPTB (Norbis et al., 2014, 
WHO, 2014). 
The clinical diversity of EPTB does not allow its diagnosis to be straightforward. 
None of the recommended diagnostic tests can be used in isolation mainly because 
most of them lack accuracy and have major drawbacks such as cross-contamination 
(Norbis et al., 2014). Culture is considered the gold standard for EPTB diagnosis in 
many countries (Davies and Pai, 2008). However, an approach where a combination 
of tests is used is still preferred (Tortoli et al., 2012, Kim et al., 2013, Valdés et al., 
1998). Currently available diagnostic tests for EPTB are discussed below. 
 
1.4.1 Smear microscopy 
The principle of this test is based on the identification of the acid-fast bacilli (AFB) 
under the microscope following staining with Ziel-Neelsen (ZN). This test however 
lacks sensitivity even though it is used as a reference standard in low to middle 
income countries (WHO, 2014). In specimens with a high bacillary load (PTB 
patients) the sensitivity is low 50-60% (Perkins and Cunningham, 2007). In 
paucibacillary specimens, the sensitivity drops below 30% such as in paediatric TB 
(Chintu, 2007) or HIV-associated TB (Harries et al., 1998). In 2007, WHO rolled out 
and issued recommendations on the use of fluorescence microscopy (Marais et al., 
2008, WHO, 2011). The principle of this technology is the identification of AFB 
after staining with auramine-rhodamine or auramine-O for visualization under the 
fluorescent microscope where the bacteria will fluoresce. The reason for the WHO 
endorsement was based on the improved sensitivity of 10% observed with this 
technology (Steingart et al., 2006). Furthermore, this technology had similar 
specificity and fast turnaround time when compared to conventional microscopy. 
However, it proved to be expensive (WHO, 2011, Steingart et al., 2006). 
Conventional microscopy is by far the simplest, most inexpensive test even though in 
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some cases more than one specimen per patient has to be processed (Craft et al., 
2000), or an additional step of sample preparation has to be performed (Peterson et 
al., 1999, Uddin et al., 2013). 
 
1.4.2 Culture 
1.4.2.1. Solid Culture 
Solid cultures are performed from clinical specimens on the Lӧwenstein-Jensen 
medium, which is egg-based, or the Middlebrook 7H9 or 7H10, which is agar-based.  
They have increased sensitivity compared to microscopy and are thus used as the 
“gold standard” in many countries (WHO, 2007). This test however requires about 3-
8 weeks before a diagnosis can be made as it depends on bacterial growth (Davies 
and Pai, 2008). When drug-susceptibility testing is required an additional 3-4 week 
turnaround is expected. Further limitations include requirement for Biosafety level 3 
(BSL-3) facilities and trained personnel; thereby precluding the use of solid culture 
in resource constrained settings.   
 
1.4.2.2. Automated liquid culture 
Compared to the solid culture, liquid culture offers increased sensitivity together 
with a speedy turnaround time of only 9-10 days. This test is based on the BACTEC 
Mycobacterial Growth Indicator Tube 960 (BACTEC MGIT 960, Becton-Dickson, 
USA), which is an improved version of the Middlebrook 7H9 broth with an oxygen-
sensitive fluorescent detection technology (Tortoli et al., 1999). Additional 
advantages of this method include the possibility of performing drug-susceptibility 
testing as well as molecular epidemiology studies (Bergmann and Woods, 1997, 
Bemer et al., 2002). When these additional tests are required, however, the time to 
diagnosis increases to 1-3 weeks. The duration of the test to obtaining results 
depends on the requested test(s). The limitation of this test is the requirement of 
highly trained personnel and high costs. Although sensitive, such long waiting 
periods before obtaining results are not helpful in managing the TB epidemic, 
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especially EPTB (Thwaites et al., 2009). For example, because an EPTB specimen 
will likely have a low-bacillary load, chances are that the culture will be incubated 
for up to 6 weeks, which will then subsequently be discarded if negative. Moreover, 
despite the desired sensitivity of this test, it still does not meet requirements of a 
POC test (as outlined in Table 1.1). 
 
1.4.3 Adenosine deaminase (ADA) 
Adenosine deaminase (ADA) is an enzyme that catalyses the conversion of 
adenosine to inosine (Piras et al., 1978) and is implicated in mononuclear phagocyte 
maturation (Carson and Seegmiller, 1976, Fischer et al., 1976). Elevated levels of 
this ADA have been reported in cases of pleural TB (Valdes et al., 1996). ADA 
testing is in a colorimetric assay format, which is inexpensive, quick and fairly 
simple to perform in diagnosing pleural TB. This test has shown increased sensitivity 
when compared to culture (Banales et al., 1991, Diacon et al., 2003). Two meta-
analyses by Greco et al and Liang et al reported sensitivity ranging between 47 and 
100% and specificity ranging between 41 and 100% (Greco et al., 2003, Liang et al., 
2008). However, when ADA levels were tested in immunocompromised patients 
such as HIV positive patients, the sensitivity was only 40-57% (Hsu et al., 1993, 
Corral et al., 2004). Therefore, testing ADA levels in pleural TB patients in an HIV-
endemic setting might not be feasible. 
 
1.4.4 Interferon-γ release assays (IGRAs) 
Interferon-γ release assays (IGRAs) are in vitro immunodiagnostic tests, which use 
whole-blood to detect TB. The principle of IGRAs is based on the measurement of 
the IFN-γ released after the stimulation of T-cells following incubation with highly 
MTBC-specific antigens such as early secretory antigenic target (ESAT)-6 and 
culture filtrate protein (CFP)-10, which are encoded within the region of difference 
(RD)-1 not found in other species of the MTBC (Lein and Von Reyn, 1997, Pai et 
al., 2004). The test has high sensitivity; patients require a single visit and it takes 
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approximately 8-16 hours before results are available. There are currently two IGRA 
tests, which have been approved by the U.S. Food and Drug Administration (FDA) 
and commercially available. The first is the QuantiFERON®-TB Gold In-Tube test 
(QFT-GIT) (Cellestis Inc., Carnegie, Australia) and T-SPOT®.TB test (T-Spot) 
(Oxford Immunotec Ltd., Abingdon, UK). The key differences between the two tests 
are outlined in Table 1.2.  These tests have sub-optimal accuracy and are unable to 
differentiate between active disease and latent infection (LTBI), especially in high 
TB or TB-HIV burden settings  (Bendayan et al., 2012, Ling et al., 2011, Santin et 
al., 2012) and thus are not suitable to diagnose active TB. Furthermore, IGRAs have 
limited accuracy in diagnosing EPTB. Dheda and co-workers evaluate the 
performance of the two commercial tests, T-SPOT®.TB and QFT-GIT using pleural 
mononuclear cells to diagnose pleural TB. They reported sensitivities of 80% and 
51%, and specificities of 65% and 94%, respectively. The T-SPOT®.TB  was more 
sensitive, however its specificity was very poor (Dheda et al., 2009). In the same 
study, unstimulated IFN-γ in pleural fluid was measured using the QuantiFERON®-
ELISA kit and yielded a sensitivity of 97% and specificity of 100%. The high level 
of accuracy using unstimulated IFN-γ suggested that it could be a good biomarker for 
the diagnosis of pleural TB (Dheda et al., 2009). A recent study investigating the 
utility of IGRAs in diagnosing EPTB reported the sensitivity and specificity of 
81.8% and 80% for TB lymphadenitis. In addition, they also reported the sensitivity 
and specificity of 38.5% and 50.0% for pleural TB (Shin et al., 2015). Moreover, a 
meta-analysis by Fan et al reported pooled sensitivity of 72% and 90%, and 
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Table 1.2: Differences in currently available IGRAs (Adapted from CDC, 2005) 
 
 QuantiFERON®-TB Gold 
In-Tube test (QFT-GIT) 
T-SPOT®.TB test (T-Spot) 
Initial Process Process whole blood within 
16 hours 
Process peripheral blood mononuclear 
cells (PBMCs) within 8 hours, or if T-
Cell Xtend® is used, within 30 hours 
 
M. tuberculosis Antigen Single mixture of synthetic 
peptides representing ESAT-
6, CFP-10 & TB7.7. 
Separate mixtures of synthetic peptides 
representing ESAT-6 & CFP-10 
 
 
Measurement IFN-γ concentration Number of IFN-γ producing cells 
(spots) 
 
Possible Results Positive, negative, 
indeterminate 




1.4.5 Nucleic acid amplification tests (NAATs) 
Molecular-based diagnostics are generally referred to as nucleic acid amplification 
tests (NAATs). These testes allow for detection of minimal amounts of DNA or 
RNA and the amplification thereof. In terms of TB, NAATs have (i) enabled 
identification of mycobacteria, (ii) detection of MTB directly from clinical samples, 
and in addition (iii) detection of drug-resistant TB (Cheng et al., 2005). They use 
different approaches, but mainly polymerase chain reaction (PCR), which can be 
conventional or real-time (Laraque et al., 2009, Reddington et al., 2011). These tests 
are based on the amplification of the DNA of either the host bacteria (M.tb) or the 
human DNA.  
 
Many researchers have developed their own “in-house” PCR diagnostic assays. 
Flores and co-workers (2005) performed a meta-analysis of “in-house” diagnostic 
PCR assays of 84 studies reporting sensitivities and specificities ranging from 9.4-
100% and 5.6-100%, respectively (Flores et al., 2005). Recently after this analysis, 
some studies reported sensitivity of 96 and 97%, and specificity of 81 and 95.3% in 
smear positive patients (Greco et al., 2009, Laraque et al., 2009). These results were 
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comparable to the commercially available NAATs developed specifically for the 
diagnosis of active TB. These include the Amplicor® mycobacterium tuberculosis 
(Amplicor MTB) assay (Roche® Diagnostic systems, Mannheim, Germany) and 
Amplified Mycobacterium tuberculosis Direct test (MTD test; Gen-Probe, San 
Diego, CA, USA), which performed with sensitivity below 95% and specificity of 
100% in smear-positive TB (Cheng et al., 2005). Both these tests have also been 
evaluated on EPTB diagnosis. However, they yielded variable results. Using the 
MTD and the Cobas Amplicor test, the sensitivities were only 33% and 55.6%, 
respectively (Lang et al., 1998, Jönsson and Ridell, 2003). In-house PCR assays on 
pleural fluid had a sensitivity of below 70% and specificity of below 90% (Villegas 
et al., 2000, Nagesh et al., 2001, Davis et al., 2011). 
 
A recent improvement of the NAAT is the Xpert® MTB/RIF assay commonly 
referred to as the GeneXpert® (Cepheid, Sunnyvale, CA, USA). The GeneXpert® is 
an automated test that uses heminested real-time PCR for the simultaneous detection 
of TB presence and drug resistance using RNA polymerase β-subunit (rpo B) gene as 
a target. The rpo B gene, a marker for rifampicin resistance, is encoded with a highly 
conserved 81-bp hot spot region (codon 507-533) comprised of more than 12 
mutations (Miller et al., 1994). Rifampicin is an important first-line drug for MDR-
TB treatment. This test is rapid with a turnaround time of 2 hours. The system is 
completely automated with the only manual step being the addition of buffer to the 
sample (Boehme et al., 2010, Helb et al., 2010). The test had a limit of detection of 
131 CFU/ml (Blakemore et al., 2010). Many studies have been carried out using the 
GeneXpert® for the diagnosis of PTB reporting good sensitivities (95-100%) and 
specificities (94-100%) (Boehme et al., 2010, Helb et al., 2010, Theron et al., 2011), 
especially in smear positive samples. 
 
With the global worry of the performance of this assay in HIV-endemic areas, where 
most TB cases are smear negative (as is also the case in EPTB), the performance was 
found to be different, with reported decreased sensitivities (49. 5% in cases of low 
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rates of HIV vs 40.6% in cases with high rate of HIV) for pleural TB diagnosis 
(Denkinger et al., 2014). In the case of TB meningitis however, the presence of HIV-
co-infection did not affect sensitivity, but the addition of a concentration step in 
sample processing enhanced the sensitivity (84.2% vs. 51.3% for unconcentrated) 
(Denkinger et al., 2014). In addition, a South African study by Bates et al revealed a 
sensitivity of 68.8% using samples obtained from paediatrics and young children 
which included induced sputum and broncho-alveolar lavage, and were smear-
negative (Bates et al., 2013). Moreover, Giang and co-workers (2015) reported a 
sensitivity of only 20.6% in paediatric TB, which was an increase of 11% of smear 
microscopy at a sensitivity of 9.2%, where they used clinical diagnosis as a gold 
standard (Giang et al., 2015). 
 
More studies were performed using different EPTB samples. In a study by Patel and 
co-workers (2013) where CSF was used for the diagnosis of TB meningitis (TBM) on 
the GeneXpert®, they reported a sensitivity of 62% compared to smear microscopy at 
12% and culture at 30% (Patel et al., 2013). Recent work in our laboratory showed 
that the accuracy of the GeneXpert® was limited when used to diagnose pleural TB, 
with the sensitivity and specificity of 22.5% and 98%, respectively (Meldau et al., 
2014). Additionally, Tortoli et al reported the sensitivity and specificity of 33% and 
100%, respectively (Tortoli et al., 2012). These data, therefore, suggest that the 
performance of the GeneXpert® for pleural TB detection is very poor. Other studies 
where lymph node aspirates and pericardial fluid were used reported suboptimal 
performance (Pandie et al., 2014, Scott et al., 2014). In contrast, improved sensitivity 
of 50-100% for lymph node TB and pooled specificity of 80% for TB meningitis 
were reported using GeneXpert®  (Denkinger et al., 2014). Therefore, the data 
allowed the WHO to consider the use of GeneXpert® in EPTB diagnosis, except for 
pleural TB (where the performance was poor). Below is a table with all the studies 
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Table 1.3: Meta-analysis of the sensitivity and specificity of Xpert MTB/RIF in the diagnosis of 
extra-pulmonary TB and rifampicin resistance in adults and children compared against culture 
as a reference standard (Adapted from WHO, Xpert MTB/RIF assay for diagnosis of PTB and 
EPTB Report, 2013). 
Specimen type Comparison to 









(pooled 95% Crl) 
 























Gastric lavage and 
aspirates 














Crl: credible interval (the Crl is the Bayesian equivalent of the confidence interval) 
 
Diagnosing EPTB, especially pleural TB, is challenging. In light of the performance 
of the diagnostic tests discussed above, the need for developing a rapid diagnostic 
test has become urgent. None of these tests are POC. However, with the 
identification of good biomarkers and development of new technologies, a rapid, 
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1.5 IDENTIFICATION OF INTERFERON GAMMA (IFN- ) AS A 
BIOMARKER FOR PLEURAL TB DIAGNOSIS 
Current biomarker discovery studies focus more on PTB than on EPTB. To date 
there is a limited number of biomarkers identified for EPTB diagnosis. One of the 
biomarkers currently identified for use in EPTB diagnostics is IFN-γ, which plays a 
fundamental role in the immune response to tuberculosis infection. The first study 
undertaken to prove this showed that activated T-helper (Th) cells tend to localise 
themselves at the site of disease and are thus capable of producing huge amounts of 
cytokines including IFN-γ (Shimokata et al., 1982). After that, a few studies further 
proved the hypothesis that individuals infected with pleural TB had significantly 
higher IFN-γ levels compared to those without TB (Kim et al., 1997, Yamada et al., 
2001, Sharma and Banga, 2004, Krenke et al., 2008, Wang et al., 2012, Keng et al., 
2013, Meldau et al., 2014). The studies reported good diagnostic accuracy with 
sensitivities between 74 and 100% and specificities of 89-100% (Kim et al., 1997, 
Yamada et al., 2001, Sharma and Banga, 2004, Krenke et al., 2008, Wang et al., 
2012, Keng et al., 2013, Meldau et al., 2014). Although these findings were 
promising, the assays used up until today are immuno-based. For examples, assays 
such as ELISA, make immunoassays still laborious, expensive, and with long 
turnaround times. One major drawback associated with this test is the batch-to-batch 
variability of the antibodies and a limited shelf life, which all leads to inconsistent 
results. To overcome this challenge, we thus explored the use of aptamers.  
 
1.6 APTAMER TECHNOLOGY 
1.6.1 What are aptamers? 
Aptamers were first discovered in 1990 by two separate research groups (Ellington 
and Szostak, 1990a, Tuerk and Gold, 1990). Aptamers are synthetic single stranded 
nucleic acid molecules specifically generated against a variety of targets such as 
proteins, peptides and whole pathogenic micro-organisms (e.g. bacteria and viruses). 
They are known to bind their targets with high affinity and specificity through a 
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lock-and-key mechanism (Figure 1.4) (Tuerk and Gold, 1990). Aptamers can also 
fold into 3D-structures, and their length ranges between 30 and 90 nucleotides 
(Brody and Gold, 2000, Hermann and Patel, 2000). 
 
 
Figure 1.4: Schematic representation of aptamer-target binding.  
Aptamers fold into 3-D nucleic acid structures that bind to target molecules via a high affinity lock-
and-key mechanism.  
 
 
1.6.2 How are aptamers made? 
The method used to generate aptamers is known as SELEX, which stands for 
Systematic Evolution of Ligands by Exponential enrichment (Ellington and Szostak, 
1990a, Tuerk and Gold, 1990). SELEX is an iterative process performed in vitro 
using a combinatorial library. It involves three major steps: (i) incubation of target 
with library, (ii) separation of target-bound from unbound sequences and, (iii) the 
amplification of target-bound sequences (Figure 1.5). The library is comprised of 
about 1015 different random sequence nucleotides which have a fixed central region 
and two primers on either side. The library is incubated with the target of interest, 
and then the unbound oligonucleotide-target complexes are separated by using a 
suitable partitioning method such as nitrocellulose membrane (Gopinath, 2007, 
Kulbachinskiy, 2007). The bound oligonucleotide-target complexes are amplified 
using PCR and universal primers. The amplified pool is then used for the next round 
of selection. Once the saturation point is reached, the pool is cloned into a vector and 
subsequently sequenced (Stoltenburg et al., 2007).  Since its inception, researches 
have optimised and modified the SELEX process. For example, Smith and 
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colleagues modified certain bases of the sequences contained in the starting library to 
ensure that the aptamers will be nuclease resistant (Smith et al., 1995). Over the years 
there have been many different SELEX protocols that have been developed and these 
are described briefly in Table 1.4. 
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Figure 1.5: The Systematic Evolution of Ligand by EXponential enrichment (SELEX) process. 
 
Briefly, typical SELEX procedures involve binding a random nucleic acid library to a target, separating the bound and unbound nucleic acids, and amplifying the 
bound nucleic acids by PCR for use in the next round of selection. After each round of selection, a smaller pool of nucleic acid sequences binding to the target is 
retained and the unbound nucleic acids are discarded. Typically, 8–15 rounds of SELEX are carried out in order to generate a pool of aptamers with sequences 
enabling the highest binding affinity for the target. These aptamers can then be cloned and sequenced. 
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Table 1.4: Timeline of SELEX procedure modifications (Adapted and modified from Millroy, 
2013) 
 
Year SELEX Name Brief description/ Improvement Reference 
 
1990 Classical Selection Generation of aptamers selected 
using recombinant proteins. 
(Teurk and Gold, 1990, 
Ellington and Szostak, 
1990b) 
 
1992 Negative selection Process used to eliminate aptamers 
that bind to the partitioning matrix 
in use. 




1994 Counter selection Similar to negative selection, 
however uses analogues of the 
target to improve the selectivity. 






Selects aptamers that contains a 
reactive groups which covalently 
links to the target. 




1995 Blended SELEX Uses an RNA library which is 
annealed to a DNA that is attached 
to an enzyme inhibitor. 




1995 Photo SELEX  Selection of aptamers that are high 
in specificity and have the ability to 
form photo induced bonds with the 
target. 
(Jensen et al., 1995a, 
Jensen et al., 1995b, 
Brody et al., 1999) 
 
 
1995 cDNA or Genomic 
SELEX 
Uses the organism’s genome to 




1996 Spiegelmers or 
Mirror-image 
SELEX 
Aptamers are chemically modified 
to include unnatural nucleotides 
making them nuclease resistant. 






Selection of aptamers by 






1997 In vivo SELEX Selected aptamers within cultured 
vertebrate cells.  
(Coulter et al., 1997) 
 
 
1998 Chimeric SELEX Generates aptamers with more than 
one function through the use of 
different oligonucleotide libraries 
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Selection is performed on mixtures 
to generate aptamers against 
complex targets. 
 
(Morris et al., 1998) 
1998 EMSA SELEX Selection through the use of 
electrophoretic mobility shift assay 
(EMSA) as a partitioning method. 




1998 Automated SELEX Uses an automated system to 
perform the SELEX for high 
throughput generation for aptamers. 




1999 SELEX against live 
organism 
Selection of aptamers through the 






1999 Multi-stage SELEX Modification of chimeric SELEX. 
The fused aptamer components 
undergo an additional selection step 
with all the targets. 





2000 Indirect SELEX Not the actual target is used during 
the selection, however the molecule 
used is target-dependent during 
binding with aptamer. 






2000 Signalling Aptamer Aptamers are labelled with 
fluorescent dyes and are able to 
detect molecules in solution. 
 




2001 Truncation SELEX Selection of aptamers by complete 
elimination or reduction of fixed 
sequences of the oligonucleotide 
library. 





2001 Crossover SELEX Two targets are used in parallel 
during the selection. 
(Hicke et al., 2001) 
 
 
2001 Toggle SELEX Aptamers able to cross-react with 
two homologous targets. 
(White et al., 2001, 
Bianchini et al., 2001) 
 
2002 Serial Analysis of 
gene expression 
(SAGE) SELEX 
Links oligomers identified from 
SELEX with longer DNA 
molecules to enhance efficient 
sequencing 
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Year SELEX Name Brief description/ Improvement Reference 
 
 
2003 SPR- SELEX Isolation of aptamers using surface 




2003 Subtractive SELEX Isolation of aptamers which are 
able to distinguish between two 
closely related structures. 




2003 Beacon Aptamer 
SELEX 
Aptamer beacons are identified 
through the use of a fluorophore 





2003 On-chip selection The technique selectively 
recognizes target using on-chip 
screening in combination with an in 
silico evolution method. 





2003 Tailored SELEX Generation of aptamers which are 
primer-free. 
(Vater et al., 2003) 
 
 
2004 Primer-free SELEX The method involves the complete 
removal of primer-annealing 
sequences prior to the selection 
process. 





2004 CE-SELEX The selection of aptamers using 
capillary electrophoresis for 







2005 FluMag SELEX The library is modified with 
fluorescein and the target is 
immobilised on magnetic beads 
during selection. 
 
(Stoltenburg et al., 
2005) 
2005 Automated SELEX The system used microfluidics and 





2006 TECS-SELEX Used to isolate aptamers for 
proteins expressed on the cell 
surface. 
(Ohuchi et al., 2006) 
 
 
2007 DeSELEX or 
Convergent SELEX 
Selection strategy to isolate both 
proteins that are abundant and less 
abundant within the same proteome 
using two different modifications to 
the conventional SELEX. 
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Year SELEX Name Brief description/ Improvement Reference 
 
 
2007 MonoLEX Generation of aptamers in a single 
round of selection.  
(Nitsche et al., 2007b, 
Peng et al., 2007, 




Procedure involves the partly 
removal of the primer annealing 
sequences prior to selection process 
(Adapted from Wen and Gray, 
2004) 





2008 Mod-SELEX Generation of aptamers which are 
nuclease-resistant through the use 
of a chemically modified SELEX 
library. 





2008 Sol-gel SELEX A SELEX-on-a-chip system, which 
utilized nanoporous sol-gel droplet 
microarrays to immobilize different 
target proteins in microfluidic 
chambers. 






2008 Cell Specific (CS) 
SELEX 
Isolation of aptamers for specific 
cell receptors (adapted from 
Homann and Goringer, 1999). 
(Shangguan et al., 
2008, Homann and 
Goringer, 1999, Kim et 
al., 2009) 
 
2009 Next generation 
SELEX 
This approach entails specifically 
designed oligonucleotide libraries 
that tile through a pre-mRNA 
sequence. The pool is then 
partitioned into bound and unbound 
fractions, which are quantified by a 
two-colour microarray. 








2009 In silico SELEX The use of computational models in 
aptamer selection. 







Selection through the use of 
microfluidic channels creating a 
miniature SELEX platform. 







Selection allows for large numbers 
of transcription factors in parallel 
through the use of affinity-tagged 
proteins (adapted from Roulet et al., 
2002). 
(Jolma et al., 2010, 
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2010 Slow Off-rate 
Modified Aptamers 
(SOMAmer) 
Selection of high-affinity aptamers 
for almost any protein target and 
the development of a novel highly-
multiplexed assay for high-
performance proteomics. 










Aptamers generated through the use 
of a fluorescence-activated cell 
sorter to differentiate and separate 
cell-bound aptamers from the non-
bound. 








Strategy for generating of aptamers 
pairs to bind distinct sites on a 
protein target. 




2012 Internalising cell 
SELEX 
The SELEX procedure is 
specifically for internalising 
aptamers. 
(Thiel et al., 2012) 
 
 
2012 GO-SELEX The procedure is based on non-
specific adsorption of ssDNA by 
graphene oxide (GO) and is an 
immobilization-free platform for 
screening of aptamers.  






2012 Capture-SELEX Selection strategy is based on 
libraries with randomized region of 
only 30-50nt split in two by a non-
variable region required for the 
capturing. 










Selection process eliminates 
unnecessary amplification steps and 
performs amplifications only when 
higher numbers pool concentrations 
are required 















AEGISs are unnatural forms of 
DNA that increase the number of 
independently replicating 
nucleotide building blocks. AEGISs 
paired and joined by different 
arrangements of hydrogen bond 
donor and acceptor groups 
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Year SELEX Name Brief description/ Improvement Reference 
 
2014 Multi-GO SELEX A simple, high-throughput aptamer 
screening for a group of small 
molecules using graphene oxide 
without target immobilization 
(adapted from Park et al., 2012) 






2014 Epitope-specific  
(ES)-SELEX 
A selection of aptamers targeting a 
specific protein epitope with the aid 
of a known and specific ligand 
competitor and report  







A semi-automated two-step method 
for in vitro selection of DNA 
aptamers using magnetic separation 
and solid-phase emulsion PCR 










Selection process used to identify 
aptamer pairs through the use of M-
SELEX and high-throughput 
sequencing (HTS) 







coupled with SPR 
evaluation  and 
HTS analysis 
Protocol developed for targeting 
small drug. Selection process 
features a long randomized 
sequence and the number of cycles 
required is reduced  







1.7 CLINICAL APPLICATIONS OF APTAMERS 
Aptamers have widely been used in both therapeutics (Nimjee et al., 2005a, Nimjee 
et al., 2005b, Keefe et al., 2010)  and diagnostics (Jayasena, 1999, Hesselberth et al., 
2000, Santosh and Yadava, 2014).  In therapeutics, aptamers need to have 
characteristics which include high specificity, stability and most importantly, be safe 
to be administered to humans. Studies have shown that aptamers do not illicit an 
immune response in therapeutic applications (White et al., 2001, Wlotzka et al., 
2002). In diagnostics, aptamers have been used in many different assay formats. 
These include biosensors, sandwich assays similar to an enzyme-linked 
oligonucleotide assays (ELONAs), imaging, and recently microarrays, to mention a 
few (Drolet et al., 1996, Bang et al., 2005, Collett et al., 2005, Cho et al., 2006, 
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Citartan et al., 2012, McCauley et al., 2003, Pultar et al., 2009, Kara et al., 2010a, 
Kara et al., 2010b, Yao et al., 2009, Yao et al., 2010). Furthermore, companies have 
been setup to exploit the SELEX technology and aptamers. Two American 
companies, namely; SomaLogic, Inc. (Boulder, CO, USA) and Archemix 
Corporation. (Cambridge, MA, USA) hold licenses in diagnostic and therapeutic 
applications, respectively. The latter was the first to produce the aptamer-based drug, 
Pegaptanib, used to treat age-related macular degeneration (ARMD). This drug 
received FDA approval in 2004. 
 
1.8 APTAMERS IN DIAGNOSTICS  
The detection of molecules from pathogens (antigens and genetic material) and host 
molecules in response to infections (antibodies) is the basic principle of molecular 
diagnostics. Up until now, antibodies are the most widely used affinity tools in 
routine diagnostics. In spite of their  relatively high production costs, reduced shelf 
life and variability in performance, antibodies are still the molecules of choice in 
diagnostic platforms (Ruigrok et al., 2011). To date, the most commonly used 
antibody-based used tests are the Western blot assay and ELISA. These tests 
however have limitations which aptamers have the potential to overcome. Thus, 
aptamers have been exploited as possible alternative tools in the development of 
different diagnostics platforms (Jayasena, 1999, Hesselberth et al., 2000, Ruigrok et 
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Table 1.5: Comparisons of properties of aptamers and antibodies 
 
Property Aptamers Antibodies 
 
Production In-vitro through chemical synthesis 
 
In vivo through the use of animal 
models 
 
Size 5-20 kDa 15-25 kDa 
 
Affinity Low nanomolar to picomolar Low nanomolar to picomolar 
 
Stability Not sensitive to temperature Sensitive to temperature and 
undergo irreversible denaturation 
 
Shelf life Long-term storage at room 
temperature 
Limited  
( require continuous cold chain 
storage) 
 
Modification Easy modification with no loss in 
affinity 
Modification may cause possible 





On/off rates can be changed on 
demand 
Cannot be changed on demand 




In diagnostics, aptamers have mostly been used in detection systems and recognition 
elements (Proske et al., 2005). A few researchers have proved the utility of aptamers 
in different diagnostic platforms (Figure 1.6) to be feasible. This was achieved by 
incorporating aptamers in lateral flow systems (Chen et al., 2012, Xu et al., 2009), 
ELONA (Ferreira et al., 2008, Guo and Kim, 2012, Pultar et al., 2009, Barthelmebs 
et al., 2011), arrays (Cho et al., 2006, McCauley et al., 2003, Platt et al., 2009, Syrett 
et al., 2009) and biosensors (Hong et al., 2012, Song et al., 2008, Kara et al., 2010a, 
Kara et al., 2010b).   
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Figure 1.6: Schematic representation of the potential applications of aptamers in diagnostics. 
 
A dry-reagent strip biosensor, also called the lateral flow biosensor using both 
conventional immunoassay and chromatography, has gained attention in clinical 
diagnostics. In one study this approach was coupled with aptamer-functionalized 
gold nanoparticles for a proof-of-concept (Xu et al., 2009). Aptamer-functionalized 
gold nanoparticles were used as probes to detect thrombin in human samples, and 
this was compared to an antibody-based strip biosensor. The proposed biosensor had 
a detection limit of 0.6pmol in the presence of other interfering proteins in the serum 
such as IgM, and outperformed the antibody-based strip in terms of sensitivity and 
specificity (Xu et al., 2009). In another study, a multiplex aptamer-based microarray 
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for the simultaneous detection of multiple analytes was developed (Cho et al., 2006). 
Two DNA and two RNA aptamers were printed on a coated slide and optimize to 
work simultaneously. In developing multiplexed protein detection microarrays, the 
critical parameters are the sensitivity, specificity, reproducibility, and signal-to-noise 
(S/N) ratio (Cho et al., 2006). Companies such as Somalogic and Achemix developed 
aptamer microarrays for the detection of photoaptamers (which could covalently 
cross-link bound protein targets) and aptamers associated with cancer proteins 
(McCauley et al., 2003, Bock et al., 2004).  
 
Tennico and co-workers (2010) developed a bead-based aptamer sandwich assay 
using microfluidics for the detection and quantification of thrombin (Tennico et al., 
2010). This approach enabled a high specificity and reduced costs.  In another study 
using an electrochemical sandwich assay, a single aptamer was used to detect 
molecules in complex matrices such as lysates and blood, with a limit of detection in 
micromolar concentration (Zuo et al., 2009). This assay was simple and cost-
effective; and performed on a format that was re-usable, making it a potential 
platform for use at POC (Zuo et al., 2009).  
 
Biosensors that employ aptamers as a recognition element are called aptasensors 
(O'Sullivan, 2002). Aptasensors have a great promise in biosensing due to their high 
sensitivity, cost-effectiveness, selectivity, portability and simple instrumentation   
(Minunni et al., 2004). A typical biosensor will consist of three components, namely, 
a biological sensing element (that “recognizes/bind” the analyte), a transducing 
element (which converts the binding/detection into a measurable signal), and a 
display, which transforms the measured signal (optical/electrical) into a digital 
format for the end user (Cheng et al., 2009). Several aptasensors have been 
developed for clinical diagnostics and those include a sandwich assay with 
electrochemical-based sensor for thrombin detection, a piezoelectric quartz crystal 
sensor for IgE quantification and a multiplex cancer marker detection system to 
name a few (McCauley et al., 2003, Centi et al., 2007, Yao et al., 2009). The main 
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advantage of aptasensors, more so electrochemical aptasesnors, is that the sensitivity 
can be enhanced by labelling the aptamer-target complex to amplify the signal. Also, 
these sensors are convenient for on-field applications as they do not require 
expensive instrumentation (Torres-Chavolla and Alocilja, 2009). To date, the most 
successful commercialized biosensor still remains the POC glucose meter reader, in 
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1.9 SIGNIFICANCE OF THE STUDY  
The burden of TB in South Africa is steadily increasing; this is partly due to the 
delay in diagnosis and treatment. Almost 500 000 prevalent cases of TB are treated 
in SA annually at great cost to the economy and human life. There is a need for an 
ASSURED POC test to overcome this challenging disease, which has been around 
for more than a century. The dual epidemic of TB and HIV also poses a great 
challenge as TB presentation in these patients is atypical. Therefore to help address 
the challenges presented by TB diagnosis, this study focused on developing an 
aptamer-based electrochemical biosensor, which would conceptually allow for rapid 
testing of EPTB, in a high-throughput platform. 
 
1.10 AIMS AND OBJECTIVES OF THE STUDY 
The aim of this thesis was to isolate and characterize ssDNA aptamers against IFN-γ 
for the development of different EPTB diagnostic tools. 
Thus, the objectives of the study were to: 
 isolate aptamers binding to IFN-γ with high affinity and specificity; 
 determine binding kinetics of IFN-γ aptamers with desirable functional 
properties such as high specificity; and  
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1.11 SCOPE AND STRUCTURE OF THE THESIS 
 
Chapter 2 describes the optimisation of the SELEX protocol for the isolation of 
ssDNA aptamers against IFN-γ. 
 
Chapter 3 focuses on the characterisation of the identified aptamers using different 
assay platforms such as ELONA and surface plasmon resonance (SPR). In addition, 
bioinformatics tools were used to determine the structural properties of the selected 
aptamers. 
 
Chapter 4 focuses on the further characterisation of the high-binding aptamers 
selected for possible use in different downstream application. In this chapter, I 
further selected one aptamer and performed different assays to characterise it for 
possible incorporation into a biosensing device. 
 
Chapter 5 summarises the overall key finding and provides recommendations and 
future work. Limitations of the study are highlighted and a general conclusion of the 
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Chapter 2: Isolation of single-stranded DNA aptamers that bind interferon- 
SUMMARY 
EPTB, a form of TB, is challenging to diagnose. Current tests rely on detecting the 
bacillus, but they perform poorly (e.g. Culture and GeneXpert). IFN-γ is a promising 
biomarker for EPTB but POC diagnostic tools are lacking.  Aptamers (described in 
detail in chapter 1) have been an attractive technology since their discovery in the 
early nineties. In this chapter, this approach is investigated using the well-
characterised EPTB biomarker; IFN-γ. I generated single-stranded DNA (ssDNA) 
aptamers using the Systematic Evolution of Ligand Exponential Enrichment process 
(SELEX). I performed eight rounds of selection and cloned the library into a vector 
at round 6, where the recovered ssDNA was 50%. Using standard molecular biology 
protocols, the final recovered pool was cloned, sequenced and screened for binding. 
The sequences were aligned and analysed for homologous residues, and to identify 
related aptamers using a phylogenetic tree. Up to 60% conservation within the 49-
nucleotide random region was found, and the consensus sequence also identified. 
Aptamers were also found in clusters on the phylogenetic tree. Five clusters and 2 
sub-clusters were identified. Some aptamers were found in duplicate and others 
appeared distantly related. Fifty four aptamers were screened for binding using 
Enzyme-linked Oligonucleotide Assay (ELONA), and 75% (41/60) significantly 
bound IFN-γ. Six of the 41 aptamers that significantly bound IFN were randomly 
selected for further characterisation through binding kinetics studies to determine 
their respective affinities. Their respective secondary structures were also determined 
using bioinformatics tools and Mfold algorithms.  
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2.1 INTRODUCTION 
The presence of HIV makes EPTB even more challenging to diagnose, and the 
incidence of EPTB is almost 5 times higher in those infected with HIV (Sharma and 
Mohan, 2004). In South Africa, where the prevalence of HIV in high, this suggests 
that EPTB is the leading cause of morbidity and mortality (Karstaedt, 2013, 
Karstaedt and Bolhaar, 2014). Clinical presentations of EPTB are diverse (Sharma 
SK, 2004). It has poor prognosis, and acid fast bacilli (AFB) smears are seldom 
positive (less than 5% of cases) (Escudero, 1990, Epstein et al., 1987). This results in 
delayed diagnosis, late treatment initiation (Golden and Vikram, 2005) and therefore 
poor clinical outcome. Because EPTB is paucibacillary, biomarkers are an important 
avenue of research. Biomarker discovery has focused more on pulmonary 
tuberculosis and not so much on the disseminated forms of TB (Fortún et al., 2014). 
Furthermore, several studies highlight how the turnaround time of the current 
existing diagnostic tools do not assist in early treatment initiation as they are 
cumbersome, laborious and expensive, with most only having moderate sensitivity 
(Dinnes et al., 2007, Pai et al., 2009, Gupta et al., 2010). POC tests are needed 
because a same day clinical outcome will be achieved where a patient does not have 
to go away before treatment is initiated. However, even though POC tests are 
available, their biggest disadvantage is that they are far away from the patients. 
Studies have shown that even though tests are available at the point of care, patients’ 
initiation on treatment is delayed (MacPherson et al., 2014, Theron et al., 2014). This 
makes the development of novel and accurate diagnostic tools, which may 
supplement or replace existing methods, a necessity (Geojith et al., 2011).  
 
Nucleic acid amplification tests (NAATs) have been attractive diagnostic tools for 
the last decade. The main advantages are the increased sensitivity, specificity and the 
turnaround time of these tests. The GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, 
CA, USA), which is a newer NAAT technology, has been shown to have overall 
good specificity and sensitivity, at 100% and 98% respectively, in pulmonary TB 
(Blakemore et al., 2010, Helb et al., 2010). This technology has also been used to 
diagnose some forms of EPTB. On pericardial TB, it showed specificity and 
sensitivity of 100%:63%, 59%:62%, respectively, and in TB meningitis 99.5%:95% 
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(Patel et al., 2013, Nhu et al., 2014). On pleural TB the performance was poor 
(sensitivities 23%; 47% and specificities of 98%; 94%) in independent studies 
carried out in South Africa recently (Meldau et al., 2014, Scott et al., 2014). The 
latest WHO report on the performance of GeneXpert MTB/RIF assay on diagnosing 
EPTB shows that most studies showed poor to moderate sensitivities with good 
specificity (WHO, 2013). So, even with NAATs improved tools for diagnosis of 
some types of EPTB, especially pleural TB are needed. A lack of good biomarkers 
has contributed to the delay of the development of POC tests for diagnosing EPTB. 
One of the most studied biomarkers is adenosine deaminase (ADA), an enzyme that 
catalyses the conversion of adenosine to inosine. This marker was first tested for its 
usefulness in diagnosing patients with pleural tuberculosis in 1987 and was also 
demonstrated to be a fairly simple test to perform (Piras et al., 1978). These tests, 
however, have moderate sensitivity and specificity (Greco et al., 2003, Goto et al., 
2003). Interferon gamma (IFN-γ), a pro-inflammatory cytokine that is produced by 
T-helper (CD4) cells and cytotoxic T-cells was discovered and its functions reviewed 
(Boehm et al., 1997, Wheelock, 1965). It has recently been shown to be a promising 
biological marker for the diagnosis of EPTB with both high sensitivity and 
specificity (Jiang et al., 2007, Eldin, 2012, Dheda et al., 2009). When used in an 
ELISA format, this marker has a specificity of 76-100%, but the sensitivity ranges 
from 11-77% (Steingart et al., 2007). Based on this evidence, I explored molecules 
known to have both good specificity and sensitivity, here after referred to as 
aptamers. These molecules are small (8-25 kDa) compared to their counterparts, 
antibodies, which are ±150 kDa in size. In addition, due to their small size, they bind 
their targets with high specificity and affinity, hence they are preferred over 
antibodies (Jayasena, 1999). 
 
Aptamers for TB have previously been isolated using targets like MPT64, 
ESAT6:CFP10, EsxG, lipoarabinomannan (LAM), H37Rv bacteria and IFN-γ 
(Rotherham et al., 2012, Qin et al., 2009, Tang et al., 2014, Ngubane et al., 2014, 
Cao et al., 2014, Chen et al., 2007, Pan et al., 2014, Balasubramanian et al., 1998). 
These aptamers were used for both therapeutic and diagnostic purposes. Both 
Rotherham et al (2012) and Tang et al (2014) isolated ESAT6:CFP10 aptamers with 
a sensitivity and specificity of 100% and 68%, and 100% and 94%, respectively, 
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using clinical samples for the diagnosis of pulmonary tuberculosis (Rotherham et al., 
2012, Tang et al., 2014). Lee and co-workers (1996) and Balasubaramanian et al 
(1998) isolated an IFN-γ aptamer to study its effect on the structure of IFN-γ and 
further demonstrated its inhibitory factor.  On the other hand, a recent study by Cao 
et al raised an IFN-γ aptamer to use in an immunological platform using intracellular 
cytokine staining (ICS) for the assessment of T-cell reactivity (Lee et al., 1996, 
Balasubramanian et al., 1998, Cao et al., 2014).  Interferon gamma has been shown 
to be significantly increased in pleural tuberculosis compared to other infectious 
diseases that illicit an immune response (Jiang et al., 2007, Dheda et al., 2009, Eldin, 
2012) . Thus, this chapter describes the development of novel ssDNA IFN-γ 
aptamers for the detection of pleural TB, with the intention to detect unstimulated 
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2.2 MATERIALS AND METHODS 
2.2.1 Isolation of aptamers against interferon gamma protein 
2.2.1.1 Recombinant interferon gamma protein 
Recombinant human interferon gamma (rIFN-γ) was purchased from Biocom 
Biotech Inc. (Pretoria, South Africa). One milligram of lyophilised rIFN-γ was re-
suspended in 1ml of distilled water to bring the final concentration to 1 mg/ml. The 
concentration was measured using the bicinchoninic acid (BCA) assay (Pierce, 
Thermo Scientific, USA) (Adilakshami and Laine, 2002, Fischer, 1999, Prozialeck, 
2002, Roberts, 2002) as described in detail below (Section 2.2.1.1.1). The size and 
quality of IFN-γ was confirmed on a sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE).  
 
2.2.1.2 Quantification of interferon gamma concentration by BCA 
The BCA assay is a sensitive colorimetric assay based on the reduction of Cu2+ to 
Cu+ by proteins. The BCA protein assay kit (Thermo Scientific Pierce, Rockford, IL, 
USA) was used to quantify total protein for all experiments. Briefly, serial dilutions 
(125-2000 µg/ml) from standards of bovine serum albumin (BSA), using distilled 
water were used to generate a standard curve. Crude protein was prepared and 10 µl 
of all samples, plus 200 µl of working reagent were loaded onto a non-protein 
binding 96-well plate (Corning, Adcock and Ingram, South Africa) and incubated at 
37 °C for 30 min. The plate was cooled to room temperature and the absorbance 
measured within 10 minutes (min) at 562 nm using a Multiskan-Go microplate 
reader (Thermo Fisher Scientific, Rockford, IL, USA). Unknown concentration of 
the interferon gamma was extrapolated by fitting a linear regression line. 
 
2.2.1.3 Analysis of protein by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis 
In order to validate the molecular weight and determine the purity of the protein, an 
SDS-PAGE was used. SDS is an amphipathic detergent, known to bind to protein in 
a non-covalent manner. It also causes proteins to denature and dissociate from each 
other, while also conferring a negative charge. To separate the protein, a 17% 
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resolving gel was prepared as outlined in Table S2.1. The gel was poured to two-
thirds of a gel casting system (Biorad Laboratories, CA, USA), and the remaining 
space was filled with 100% ethanol (Merck, Darmstadt, Germany) to ensure an even 
surface while setting.  After setting, the ethanol was poured off and the 4% stacking 
gel (Table S2.2) layered on top of the resolving gel. 
 
2.2.1.4 Aptamer libraries 
The first step in Systematic Evolution of Ligand by Exponential enrichment 
(SELEX) process (Figure 2.1) was to create a pool of variant sequences from which 
RNA or DNA ligands of relatively high affinity for target proteins can be selected. A 
library comprised of a central randomized region of 20-80 nucleotides, flanked by 
constant regions, which are used as primer annealing sites for the selection is 
commonly used for SELEX.  The length of the random region determines the 
complexity of the library. Therefore, a library with a random region of about 20 
nucleotides will yield 420  unique sequences  (Sassanfar and Szostak, 1993, Jayasena, 
1999). The molecular diversity of a library depends on the number of randomized 
nucleotide positions. In theory, a library with a 40nt random region is represented by 
1.2 x 1024 individual sequences, simply put 440 = 1.2 x 1024. Typically, libraries of 
1014- 1016 of ssDNA fragments are preferred (Marshall and Ellington, 2000, Pan and 
Clawson, 2009).  
 
Usually, shorter random regions are preferred as they are just as efficient, cost-
effective and much better manageable (Jayasena, 1999). It is not uncommon though 
to use libraries with longer random regions (up to 120 nucleotides), especially for 
RNA libraries. They have the ability to form a variable number of different structures 
and increase the complexity of sequences, increasing the efficiency of the selection 
method used (Conrad et al., 1996) and providing better opportunities for the 
identification of aptamers (Marshall and Ellington, 2000). In most cases though, long 
aptamers end up being truncated as they prove to be cumbersome and unmanageable. 
Therefore, these aptamers are truncated to yield shorter functional derivatives, as 
shown by Bock et al, who truncated the human thrombin DNA aptamer comprised 
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on a 60 nucleotide random region, to a mere 15 nucleotide, which retained the same 
binding affinity.  
 
For the selection of ssDNA IFN-γ aptamers, a 90mer oligonucleotides library 
randomized at 49 nucleotide positions and primers were designed and synthesized by 
Integrated DNA Technology Inc. (Integrated DNA Technology Inc, Iowa, USA). 
The library used was flanked by constant regions, which were used as primer 
annealing sites for the selection. The forward primer was modified with biotin at the 
5ʹ-end and the reverse with phosphate at the 5-end. The oligonucleotide library and 
primer sequences are listed in Table S2.3. 
 
2.2.1.5 In vitro selection of ssDNA aptamers 
During the selection process, molecules that bind the target with high affinity and 
specificity will be identified from the thousands of sequences contained in the 
oligonucleotide library. In most cases selection conditions play a great deal in the 
properties of the aptamers to be obtained. For example, the number of rounds to be 
performed depends on the degree of stringency introduced at each round. 
Furthermore, the type of molecule used as the target, the type of oligonucleotide 
library, and the partitioning method used all play a great role in the selection process 
(Stoltenburg et al., 2007). For instance, the conditions can influence the secondary 
structure, specificity, affinity, stability, and most importantly the dependence or 
absence thereof of specific ions and salts to promote binding to the target (Irvine et 
al., 1991). 
 
SELEX consists of three main stages: (i) the incubation of the oligonucleotide library 
with the target; (ii) the partitioning of target-bound complexes from non-binders; and 
(iii) the amplification of the target-bound complexes (detailed steps of the selection 
procedure are presented in Chapter 1, Figure 1.5). The procedure consists of several 
rounds of the three main stages, where an enrichment of several orders of magnitude 
is expected after each round. On average 5-15 rounds is sufficient to produce good 
quality aptamers. A standard SELEX protocol was carried out as set-out below.  
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2.2.1.5.1 Incubation of interferon gamma with oligonucleotide library 
Prior to the positive selection, the library was incubated with the nitrocellulose 
membrane in absence of the target (negative selection). This was done to eliminate 
sequences that specifically bound to the membrane. For the positive selection, 500 
pmol of ssDNA library was used in order to obtain a diversity of at least 1014 unique 
sequences. The ssDNA library was refolded in 1 HMCKN selection buffer (20 mM 
Hepes, 2 mM MgCl2, 2 mM CaCl2, 2 mM KCl, 150 mM NaCl; pH 7.4) by being 
denatured at 95°C for 3 min, renatured by immediately cooling on ice for 5 min and 
then left to reach room temperature. This was done to allow the nucleotides to 
dissociate from other conformations they could possibly be in, and assume their most 
stable conformation when in selection buffer. Twenty microliters of IFN-γ protein (1 
mg/ml) was added and the mixture incubated for an hour at room temperature. 
Stringent conditions were introduced only after round 3, where the number of washes 
were increased from one to two. This was after the selection progress showed a 
steady increase. This was followed by an additional 2 rounds of positive selection, 
before a negative selection was introduced after round 5. Other stringent conditions 
such as a change in salt concentration or a decrease in target (IFN-γ) to ssDNA ratio 
were kept constant throughout the selection process. 
 
2.2.1.5.2 Partitioning of target binders from non-binders 
The most critical step in the selection process is the partitioning of target-
oligonucleotide binders from non-binders. This can be achieved using different 
methods as described in detail in a review by Gopinath (2007). The nitrocellulose 
membrane is commonly used for partitioning (Tuerk C, 1990, Ellington and Szostak, 
1990b). It is easy to use as there is no need for the immobilisation of the target on a 
surface. Since nitrocellulose membranes (Merck, Millipore, Germany) have been 
shown to bind non-specifically to proteins (Tuerk C, 1990, Schneider et al., 1992), it 
was crucial that a negative selection be performed prior to each positive selection. 
Generally this partitioning method is preferred for protein targets (Gopinath, 2007).  
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The nitrocellulose membrane (Merck, Millipore, Germany) was pre-treated with 0.5 
M KOH solution for 20 min at 22°C, rinsed extensively with dH2O, then soaked in 
100 mM Tris-HCl (pH 7.5), and subsequently stored in the same buffer at 4°C. This 
caused the membrane to be fragile, and caution when handling was necessary. The 
membrane was soaked in 1 HMCKN selection buffer for an hour. The pre-treated 
membrane was then locked into a filter disk holder and ssDNA-protein complexes 
were passed through. This was followed by washing three times with 300 µl 1 
HMCKN binding buffer to eliminate all non-specifically bound oligonucleotides. To 
elute the bound ssDNA-protein complexes, the membrane was transferred to a clean 
glass plate and cut into 8 pieces using a sterile scalpel blade.  The pieces were then 
transferred into a microcentrifuge tube, and 200 µl of elution buffer (100 mM 
Sodium citrate, 3 mM EDTA, 7 M urea) added. The solution was heated at 100°C for 
5 min to release the bound complexes from the membrane. This was followed by an 
addition of 600 µl of phenol chloroform (pH 7.9), and an incubation of 25 min before 
extraction. Subsequently, the aqueous solution was removed and precipitated by 
adding 150 µl of 3 M sodium acetate (pH 5.2) and 1 ml of 100% ethanol (Merck, 
Darmstadt, Germany) and stored overnight at -80°C. The next day, the recovered 
ssDNA was centrifuged at 14 000 rpm for 30 min at 4°C. The supernatant was 
decanted and the pellet washed once with 70% ethanol, and left to air dry before 
being re-suspended in 30 µl sterile dH2O. The ssDNA was quantified using the 
Nanodrop® ND-100 spectrophotometer v3.0.1 (Thermo Scientific, MA, USA) and 
the percentage recovery determined. 
 
2.2.1.5.3 Amplification of target-bound pool by PCR 
The recovered ssDNA pool was amplified using PCR under mutagenic conditions 
(Table S2.4 and Table S2.5) in order to increase the variation of the molecules 
(Cadwell and Joyce, 1994).The unusually high Taq polymerase and MgCl2 
concentrations increased the error rate of PCR by stabilizing the non-complementary 
pairs and increasing the pH (Cadwell and Joyce, 1992, Leung et al., 1989). It is 
crucial however, that this is carried out in an unbiased fashion. Therefore, over 
amplification needs to be avoided as this only increases the yield, but not the 
diversity per se. Most of the mutations introduced are point mutations and they are 
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commonly AT or TA substitutions. A pilot PCR was setup in order to determine 
the minimum number of cycles needed to optimally amplify the pool. A reaction 
master mix was set-up using 10% of the recovered ssDNA. The master mix was 
aliquoted equally into four 0.2 ml tubes and PCR performed for 4, 6, 8 and 10 cycles 
respectively. A non-template control (NTC) was included in every PCR experiment. 
The samples were subsequently analysed on a 12% non-denaturing PAGE (Table 
S2.6), stained with ethidium bromide, and viewed using ultraviolet (UV) trans-
Illuminator GelDoc™ XR system (Biorad Laboratories, CA, USA). Five microliters 
of low range DNA marker (Fermentas, Thermofisher Scientific Inc., MA, USA) were 
loaded in order to determine the correct size of the band. PCR reactions were then 
prepared with the entire ssDNA pool, using the appropriate number of cycles (as 
determined by the pilot PCR). Products were pooled (including the one used for the 
pilot PCR) and subsequently purified using the Nucleospin Extract II PCR cleaning 
kit (Macherey-Nagel, Dϋren, Germany), as outlined by the manufacturer. The 
purified dsDNA was quantified using the Nanodrop® ND-100 spectrophotometer 
v3.0.1 at 260nm (Thermo Scientific, MA, USA). 
 
2.2.1.5.4 Generation of ssDNA by Lambda exonuclease digestion 
Single-stranded DNA is required to perform the SELEX, and it is an essential and 
also important step. The Lambda exonuclease method was used to generate the 
ssDNA. This method required that the reverse primer of the SELEX be phosphate- 
labelled at the 5-end, which will allow the one strand of the double-stranded 
(dsDNA) to be phosphorylated, then subsequently digested with the lambda 
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Figure 2.1: The Lambda Exonuclease digestion process. 
Lambda exonuclease is a recombinant enzyme that digests a single strand of a duplex DNA in the 5’-3’ direction. 
The 5’-end will be phosphorylated and generating single-stranded DNA. An enzymatic procedure where double 
stranded DNA is digested to single-stranded DNA by means of the lambda exonuclease enzyme digesting on the 
5’-phophate labelled end of the sequence.  
 
About 6.6 µg of the generated dsDNA, was lambda exonuclease digested (Figure 
2.1) by adding 10 µl of exonuclease buffer (10) (New England Biolabs® Inc., MA, 
USA), 6 µl of exonuclease enzyme (50 U) (New England Biolabs® Inc., MA, USA) 
and water up to a total volume of 100 µl. The reaction mixture was incubated for 4 h 
at 37°C and terminated by incubating at 72°C for 10 min. The ssDNA was then 
purified using the Nucleospin Extract II PCR cleaning kit (Macherey-Nagel, Dϋren, 
Germany), according to the manufacturer’s guidelines, and quantified on the 
Nanodrop® ND-100 spectrophotometer v3.0.1 at 260nm (Thermo Scientific, MA, 
USA). A 12% non-denaturing PAGE with a dsDNA product as a control was run to 
determine the purity and quality of the ssDNA. The enriched ssDNA pool was now 
ready for the next round of selection. 
 
2.2.2 Cloning and sequencing of ssDNA aptamers 
In order to further characterize the aptamers, their sequences had to be known. This 
was accomplished by cloning the final recovered aptamer pool from the SELEX. 
After the highest recovery of ssDNA was determined at round six, following an 
introduction of a negative selection (in the absence of the target protein), the 
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recovered pool was cloned. First, the pool was amplified and ligated into a pGem-T 
Easy vector (Promega, WI, USA). The ligation reaction was prepared as outlined in 
Table S2.7, following an incubation step for 1 hour at room temperature with slight 
agitation. Transformation was carried out by inserting the vector construct into 
competent E. coli TOP10 cells (Invitrogen, CA, USA). Briefly, two microliters of the 
ligation reaction as set out in Table S2.7 were added to 50 µl of cells and incubated 
on ice for 20 min, with occasional mixing. Cells were then heat shocked at 42°C for 
exactly 45 s, and immediately put back on ice for 2 min. SOC medium (Invitrogen, 
CA, USA) was added to the cell mixture to a final volume of 1 ml, and incubated at 
room temperature for 1½ h while shaking. A 100 µl of the mixture was plated onto 
ampicillin positive nutrient agar plates (Sigma-Aldrich, MO, USA) and incubated 
overnight at 37°C.  
 
After transformation, 96 colonies were randomly picked and spread onto Luria Broth 
(LB) agar plates (5% NaCl, 5% yeast extract, 10% tryptone) containing 100 µg/ml of 
ampicillin (Sigma-Aldrich, MO, USA) and 5-bromo-4-chloro-3-indolyl-β-d-
galactopyranoside (X-gal) for blue-white colony screening. Clones were sequenced 
with M13 universal primers (pUC/M13): primer forward: 5-
CCCAGTCACGACGTTGTAAAACG-3 ; reverse primer: 5-
AGCGGATAACAATTTCACACAGG-3 (Inqaba Biotech, Pretoria, South Africa). 
Glycerol stocks were prepared by making overnight cultures from the 96 randomly 
picked colonies. The following day the cultures were centrifuged and the pellet and 
transferred to Eppendorf tubes, and Tween 20 added to the tube. The tubes were 
snap-freezed using nitrogen and stored at -80°C for future experiments. The analysis 
of sequences was done using the CLC Sequence Viewer v7.5 
(http://www.clcbio.com) (CLC Bio, Aarhus, Denmark), and CLUSTAL W 
(http://www.ebi.ac.uk/clustalw/) application of BioEdit v7.1.3.0 (Hall, 1999). 
Sequences were aligned to identify and assess conserved motifs; and to also generate 
a maximum likelihood tree. Bootstrapped neighbour joining phylogenetic tree with 
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2.2.3 Binding assay of ssDNA aptamers using the ELONA 
ELONA was used to determine the binding of the aptamer to the target, IFN-γ 
(Figure 2.2). This procedure was first described by Drolet and co-workers in1996. A 
96-well microtitre plate (Corning, Adcock and Ingram, South Africa) was coated 
with 10 µg/ml of protein in 10 mM NaHCO3 coating buffer (pH 8.5) using 50 µl per 
well. The plate was sealed and stored at 4 °C overnight. On the second day, the plate 
was washed three times with 100 µl of phosphate buffered saline containing 0.05% 
(v/v) Tween-20 (PBS-T) (pH 7.0) (Sigma-Aldrich, MO, USA) and blocked with 150 
µl of 10% (w/v) fat-free milk, then incubated for one hour at 4°C. The plate was 
washed four times with 100 µl PBS-T and blotted dry after the last wash. Aptamers 
were prepared at a final concentration of 300 nM and then denatured at 95°C for 3 
min, cooled on ice for 5 min, and brought to room temperature before being used. 
Fifty microliters of each aptamer was added to each well in triplicate.  
 
Three controls were included on each plate. These included the blank (buffer only), 
aptamer alone control (in absence of IFN-γ) and the IFN-γ-alone control (in absence 
of aptamer). The plate was sealed and incubated at room temperature for two hours. 
Then it was washed three times with 100 µl of PBS-T and blotted dry after the last 
wash. Fifty microliters of Streptavidin-conjugated HRP (diluted 1:10 000 in PBS-T) 
(Kirkegaard & Perry Laboratories, MD, USA) was added to each well and the plate 
sealed and incubated at 37°C for two hours. The forward primer used for PCR was 
modified with biotin at the 5-end, in order to enable the aptamer to react with the 
streptavidin-conjugated HRP in this procedure. After two hours, the plate was 
washed three times with 100 µl of PBS-T and blotted dry after the last wash. The 
substrate was prepared by adding equal volumes of peroxidase solution and 3, 3, 5, 
5 tetramethylbenzidine (TMB) solutions (Thermo fisher Scientific, Rockford, USA), 
and 50 µl was added to each well. A blue colour change was seen almost instantly 
with the naked eye. The reaction was terminated by using a 2 M sulphuric acid 
solution, which changed the colour from blue to yellow. The plate was read on a 
Mulitskan-Go microtitre plate reader (Thermo Scientific, MA, USA) at 450 nm.  
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Figure 2.2: Detection of IFN-γ by biotin-conjugated aptamers using ELONA. 
In a separate well, IFN-γ was coated and an aptamer introduced after washing and blocking with 10% fat-free milk. 
A streptavidin-HRP conjugated enzyme was introduced and the TMB chromogenic substrate added before reading 
at 450nm on a plate reader. 
 
Each aptamer was tested in triplicate, in two independent experiments performed on 
different days. The repeats were averaged and the standard deviation calculated. The 
buffer only (blank) was averaged and subtracted from each well, in order to get rid of 
the background noise. The data was then normalized using the aptamer alone control. 
The aptamers were then compared to the aptamer alone control using an unpaired 
two-tailed t-test to determine which aptamers had a significantly higher binding 












Chapter 2: Isolation of single-stranded DNA aptamers that bind interferon- 
2.3 RESULTS 
2.3.1 Determination of protein concentration for in-vitro selection 
2.3.1.1 Concentration of interferon gamma for use in SELEX 
In order to use the correct concentration of the target (in this case IFN-γ), in the 
selection process, the concentration of the stock needs to be determined, such that the 
correct dilutions are carried out accordingly, to yield the desired final concentration. 
The expected concentration of IFN-γ was 1000 µg/ml. Therefore, a range of 
standards between 250-2000 µg/ml was prepared. The unknown concentration was 
extrapolated and is highlighted in red, on the graph (Figure 2.3A). The quality and 
the size of IFN-γ were determined on a SDS-PAGE (Figure 2.3B). The size of IFN-γ 
measured at 17 kDa, which was the expected size. 
 
 
Figure 2.3: A standard curve plotted from the standards used ranging between 0-2000 µg/ml 
and a 12% sodium dodecyl sulphate-polyacrylamide gel of IFN-γ. 
(A) A standard curve was used to extrapolate the concentration of the unknown protein. The closeness 
of fit determined by adding a linear regression line was calculated and found to be R2=0.9303. The 
calculated concentration of the unknown protein was found to be 1.1 mg/ml, using the y=ax+b equation. 
(B) The reconstituted protein was analysed to confirm the size and the absence of contaminating 
proteins. The size was determined by using a protein marker (Promega, WI, USA), measuring in 
kilodaltons (kDa). M: Marker; IFN-γ: interferon gamma protein. IFN-γ is measuring at the appropriate 
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2.3.2 Isolation of aptamers against interferon-γ 
2.3.2.1 Validation of SELEX library and lambda exonuclease digestion 
SELEX was performed as described by Jhaveri and Ellington, (2001) using slight 
modifications. During each SELEX cycle performed, the recovered pool had to be 
amplified using PCR. Four to twelve cycles of PCR were done where tubes were 
removed after every 2 cycles. The recovered pools were subsequently run on a 12% 
non-denaturing PAGE, followed by staining with ethidium bromide (Figure 2.4A). 
Six cycles of PCR were optimal to amplify the pool. Therefore, the remaining final 
recovered pool was amplified using 6 cycles of PCR. Over amplification was seen 
from round 8 to round 12 (Figure 2.4A). The non-template control (NTC) showed no 
presence of any artefacts or contaminants. The product size was the expected 90 bp, 
as confirmed by the DNA ladder loaded on the far left lane of the gel. 
 
Following the amplification of the recovered pool, the dsDNA was purified and the 
ssDNA obtained by lambda exonuclease digestion (as described in Section 2.2.1.4). 
After this process, the obtained digested ssDNA was purified accordingly, quantified 
and validated on a 12% non-denaturing PAGE to ensure complete digestion of the 
one strand (Figure 2.5B). A dsDNA product was included as a control. A slightly 
higher band is usually seen, should the incubation of the dsDNA and the exonuclease 
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Figure 2.4: Polyacrylamide gels of single stranded DNA and validation following exonuclease 
digestion. 
(A) Amplified product of ssDNA pool after each round of SELEX was validated on a 12% non-
denaturing PAGE. A total of 12 PCR cycles were performed and tubes were removed at the 4th cycle, 
and for each 2nd cycle after that. Lane 1: DNA ladder (25 bp), lane 2: ssDNA at 4 cycles, lane 3: ssDNA 
at 6 cycles, lane 4: ssDNA at 12 cycles, lane 5: ssDNA at 10 cycles, and lane 6: non-template control 
(NTC). (B) Validation of ssDNA on 12% non-denaturing PAGE following lambda exonuclease 
digestion for 4 h at 37°C. The product was purified using Nucleospin ssDNA clean-up kit (Separations), 
and a special buffer for ssDNA was used. A dsDNA product was included as a control to ensure that no 
dsDNA was left following the digestion. Lane 1: DNA molecular weight marker, lane 2: double-
stranded DNA (dsDNA), lane 3: single-stranded DNA (ssDNA). 
 
2.3.2.2 Recoveries from selection 
Six rounds of SELEX were optimal for the positive isolation of IFN-γ binding 
ssDNA aptamers. Eight rounds were performed, where a gradual increase in recovery 
was observed from round 1-3 at recoveries of 0.5%, 7% and 22.3% (Figure 2.5), 
epitomising the exponential increase expected to be seen. However, a sudden 
decrease in percentage recovery was then identified at rounds 4 and 5 (5% and 7%, 
respectively), which was then followed by an introduction of a negative selection 
(where non-specific binders to the nitrocellulose membrane were removed). An 
arrow on the graph was used to indicate where the negative selection was done 
(Figure 2.5). Upon continuation of positive selection, a significant increase was 
obtained at round 6 with a recovery of 49.9% of ssDNA (Figure 2.5). An aliquot of 
the recovered pool was kept for cloning before continuing with the selection. A 
decline was observed at rounds 7 and 8 with recoveries of 7% and 13%, respectively 
(Figure 2.5). For this reason it was decided to stop the selection. 
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Figure 2.5: The percentage of IFN-γ binding ssDNA pool recovered at each round of SELEX. 
Eight rounds of selection were performed and cloning done at round 6, which had the highest recovery 
of almost 50%. The arrow depicts where the negative selection (in absence of target) was done. A 
decline was observed at rounds 6 and 7. 
 
2.3.3 Analysis of ssDNA aptamer sequences 
2.3.3.1 Sequence alignment 
In order to identify sequences of the aptamers, clones were sequenced and 
subsequently analysed using CLC Sequence Viewer v7.5 (Figure 2.6). Some 
sequences were found in duplicates; A7 and F5, A9 and G6, B2 and G7, E1 and H11, 
F7 and E2, F3 and G3 (Figure 2.6). Aptamer F4 differed by 1 base pair compared to 
F5 and A7; and aptamers A4 and F8 had a 2 base pair difference,  and the rest of the 
sequences were unique. One aptamer, H9, was found to be 48nt long. This could 
have been caused by the high error rate of Taq polymerase per nucleotide per pass 
during mutagenic PCR (Cadwell and Joyce, 1994). Some aptamers’ sequences had a 
trail of Ts e.g. G5, B2, and B12. Conservation within the 49mer motif generally 
ranged between about 30 and 61%; except for bases 24 and 25, with only 8% 
conservation. The highest conservation was seen at base position 43, at 61%. The 
flanking sides (forward and reverse primers) had 100% conservation as expected. For 
a complete alignment with primers (see Appendix 2C). The consensus sequence for 
the motif is shown in a red box at the bottom of the alignment, and the base 
percentages and other nucleotide statistics can be found in Appendix 2D. Sequences 
which had incomplete or missing primer sequences; those whose chromatograms 
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could not be accurately read, those who had chunks of the 49-nucleotides motif 
missing, and those with the letter “N” were excluded from the multiple alignment.  
 
Figure 2.6: The tabular format of a multiple alignment of 36 IFN-γ DNA sequences identified in 
the 5-3 direction. 
Sequence identification appear at the beginning of each row and the position of each base is indicated 
by the numbers at the top of the alignment columns. The number at the end of the sequence indicated 
the number of nucleotides for each sequence. The level of sequence conservation is shown at the bottom 
of the alignment in pink, with a scale of 0-100% located on the left. The primers on the flanking sides 
of the motif, are the most conserved. The red box indicates the consensus sequence of the 49mer motif. 
Duplicate sequences were identified and are illustrated by matching stars. The gaps represent where the 
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2.3.3.2 Phylogenetic analysis 
An unrooted phylogenetic tree was constructed using CLUSTAL W to compare the 
divergence of the aligned aptamer sequences. The bootstrap was set to 1000 
replicates, which was a means of measuring the phylogenetic accuracy. The aptamers 
seemed diverse, which could be an indication of increased specificity to IFN-γ. The 
aptamers shared homology as indicated by the short horizontal branches, which were 
drawn proportional to the number of base pair difference between two sequences 
(Figure 2.7).  
 
 
Figure 2.7: A phylogenetic neighbour joining tree following multiple alignment. 
The length of branches was directly proportional to the base difference between aptamers. Aptamers that are 
clustered are grouped (shown in blue rectangles) and sub-clusters are shown in orange. In total, 5 clusters (1, 2, 3 
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When the tree was studied closely it was observed that sequences could be clustered 
into 5 groups, labelled as 1, 2, 3, 4 and 5; and two more sub-clusters, labelled i and ii, 
were seen within clusters 1 and 4, respectively. One main outlier, aptamer A1 was 
found. This aptamer branched from the main branch, which suggests that its 
sequence was the most different from the rest of the other aptamers. Another 
possibility could be the type of secondary structure that it forms upon binding IFN-γ. 
The six aptamer duplicates seen in the multiple alignment (Figure 2.7), are seen on 
the tree (in red circles), where they were found on the same position on the branch. 
Those aptamers were: G6 and A9; G7 and B2; E2 and F7; A7 and F5; E1 and H11; 
G3 and F3. Aptamers F8 and A4 had a 2 base difference, while aptamer F4 was 
different with one base to aptamers A7 and F5.  Only one of the duplicate aptamers 
was included in subsequent assays. This neighbour joining tree does not provide 
details of ancestral sequences. Therefore, the ancestral history of the sequences that 
were contained in the final recovered pool is not known. 
 
2.3.4 ELONA-based identification of IFN-γ binding aptamers after SELEX 
In parallel with the bioinformatic analyses, we used ELONA to measure the binding 
of the candidate aptamers to IFN-γ. Only one of each duplicated aptamer was 
included in the screening. Therefore, of the 60 aptamer clones aligned, only 54 were 
screened following the SELEX (Figure 2.8). An aptamer alone control was run for 
each aptamer and used to normalise the data. Out of the 54 biotinylated ssDNA 
aptamers screened, 68% (41/60) bound to IFN-γ significantly (p <0.05). Nineteen 
aptamers bound IFN-γ with p≤0.001, 13 with p≤0.01 and 9 with p≤0.05, when 
compared to the aptamer alone control (Figure 2.8). 
 
56 
Chapter 2: Isolation of single-stranded DNA aptamers that bind interferon- 
 
 
Figure 2.8: Binding of ssDNA aptamers for IFN-γ.   
 
P-values are for comparisons in OD between wells containing IFN-γ and aptamer versus wells containing the aptamer without IFN-γ.  Fifty microliters of IFN-γ (1 
µg/ml) in HMCKN binding buffer (pH 7.4) was pipetted into a 96-well microtitre plate in triplicate. Individual aptamers (300 nM) were added and three controls, 
blank (HMCKN binding buffer only), aptamer alone, and IFN-γ alone, were included. An aptamer alone control was included for each aptamer, but only the OD for 
one (aptamer H12) was shown for illustrative purposes. A two tailed t-test was used to determine the p-values. The experiment was done at least twice in triplicates. 
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2.4 DISCUSSION 
This chapter describes the results of the SELEX procedure used for the isolation of 
IFN-γ binding aptamers, the subsequent analyses of the aptamer sequences and their 
binding to IFN-γ. The three key findings were: (i) Ninety six aptamers were isolated 
against IFN-γ; (ii) There was up to 61% homology between aptamers (iii) A total of 
41 aptamers bound significantly to  IFN-γ when compared to the aptamer alone 
control (p<0.05). 
 
We used SELEX to isolate ssDNA aptamers that bound IFN-γ. Eight rounds were 
performed with a round of counter selection introduced after round 5. Usually, it is 
recommended that 6-15 rounds be performed in order to isolate aptamers with high 
binding affinity and specificity (Jayasena, 1999, Gopinath, 2007). The protocol used 
proved sufficient after only eight rounds, where an enrichment of 50% was achieved. 
The recovered ssDNA pool was subsequently cloned and sequenced.  Specifically, 
96 clones were randomly selected and sequenced. These results are consistent with 
Bock and co-workers’ (1992) experimental approach and findings. Their SELEX 
against thrombin also achieved an enrichment of ~40% at round five where they 
cloned (Bock et al., 1992). The percentage increase of 0.01% at round one in the 
study by (Bock et al., 1992) was comparable to the current study at 0.5%. In another 
SELEX study  that isolated ssDNA aptamers  against TB-related protein CFP-
10:ESAT-6 final recoveries were between 55% and 68% (Rotherham et al., 2012).  
Similarly, Barfod et al achieved a  recovery of 58% when isolating aptamers against 
malaria species, plasmodium falciparum (Barfod et al., 2009).  
 
The number of aptamers obtained from the final recovered pool depends on the 
conditions of the selection process,  stringency and the nature of the target molecule 
used (Nieuwlandt, 2000). It was important to study the different aptamer sequences 
using bioinformatics tools, which allowed for categorisation of the homologous 
sequences. Sequencing revealed that the aptamers in the final recovered pool shared 
sequence homology to one another and the consensus sequence was determined. This 
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observation suggests that there was a convergent evolution during the SELEX 
process.  
 
Although there was a degree of homology, some aptamers were distantly related, 
indicating that they likely had a different mechanism of binding, or they were 
binding to different epitopes of the IFN-γ.  Aptamer H9 had a sequence length of 
48nt instead of 49nt. However, this phenomena has been seen before (Wang et al., 
2013). Aptamers were found in clusters, which further confirmed their relation as 
shown on the phylogenetic tree (Figure 2.8). The algorithm used in this analysis 
solely depended on distance, which was calculated to be directly proportional to the 
number of base difference per sequence (Sleator, 2011, Saitou and Nei, 1987). The 
motifs identified following the alignment are believed to be involved in the specific 
target binding of the aptamers (Stoltenburg et al., 2007), where secondary structure 
predictions can also be determined using the same sequences. This is supported by 
findings from a study by Gopinath and colleagues (2006b) who isolated an RNA 
aptamer that bound specifically to the haemagglutinin of influenza B virus, but failed 
to bind when a new aptamer was developed using the complementary sequence of 
the original aptamer. It could also be possible that the aptamer with the 
complementary sequence was assuming a different secondary structure (upon 
binding target) from the original. This clearly demonstrated that the random region of 
the original aptamer was responsible for binding (Gopinath et al., 2006b). This is 
discussed further in Chapter 3.  
 
Different binding patterns were observed from duplicate sequences, which can be 
attributed to the secondary structures that the aptamers conform when binding to 
IFN-γ. Interestingly, these seemed to be the most abundant candidate aptamers 
present in the final selection round. The majority of those that bound IFN-γ 
significantly were found in clusters as seen on the phylogenetic tree (Figure 2.8). 
Additionally, the phylogenetic tree algorithm which was used to perform the analysis 
of the closely related aptamers was based solely on the sequence and not on the 
structure of the aptamer. Because the binding of the aptamer to its target is based on 
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its structure, looking into the analysis of the secondary structures of those specific 
aptamers could provide further insight. None of the aptamers isolated and sequenced 
in the current study matched the two previously published IFN-γ aptamers 
(Balasubramanian et al., 1998, Cao et al., 2014), when their sequences were 
compared. Thus, Balasubramanian and co-workers (1998) isolated a 26mer IFN-γ 
aptamer that could alter the structure of the IFN-γ protein. Also, another group most 
recently developed a 59mer aptamer that could be used to evaluate intracellular IFN-
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2.5 CONCLUSION 
Aptamers binding IFN-γ were isolated, their sequence homology analysed and their 
binding determined. A substantial number of aptamers significantly bound IFN-γ and 
they shared a degree of homology. Some of these differences could be attributed to 
the conditions with which the SELEX was carried out. One important limitation is 
that not the entire final recovered pool was sequenced. Clones were randomly picked 
and processed for sequencing. As a result this led to only a few sequences being 
identified. Additionally, some sequences were eliminated due to various reasons 
discussed in Section 2.3.2.1. High-throughput sequencing platforms like Illumina 
(Schütze et al., 2011, Cho et al., 2010, Guo et al., 2014, Ngubane et al., 2014) are 
therefore recommended to overcome this limitation as they produce a significantly 
higher number (thousands-millions) of reads. This can also be coupled with parallel 
quick binding characterization (Cho et al., 2013). Furthermore, recovered pools at 
each SELEX cycle could have been sequenced. That would have allowed for the 
monitoring of the SELEX experiment, which is crucial in maintaining a balance 

















CHARACTERISATION AND BINDING 








The affinity and stability of aptamers is determined by their 3D structures. In the 
previous chapter I described 45 ssDNA aptamers that bound significantly to IFN-γ 
(p<0.05). In this chapter, I describe secondary structure prediction of the six 
aptamers randomly selected from the 45 that bound significantly to IFN. This 
chapter also describes the limit of detection (LOD) and the period of time needed to 
reach saturation (time-course assays) by each of the six aptamers. Furthermore, I 
describe the constant rates; association constant (Ka), dissociation constant (Kd), and 
the equilibrium dissociation constant (KD) for each aptamer, using surface plasmon 
resonance (SPR). When predictions of secondary structures were done, each aptamer 
had a maximum of six possible stable structures they could adopt upon binding IFN-
γ. In addition, aptamers A1 and B4 could fold into G-quadruplex structures, which 
was attributable to their G-rich sequences. Binding efficiency studies revealed a 
LOD of 10 µg/ml. Moreover, at this specific IFN-γ concentration (10 µg/ml), 
aptamers A1, B2 and B4 bound in an aptamer concentration-depended manner, 
whereas aptamers A2, A9, B2 and H12 reached saturation at an aptamer 
concentration of  75 nM each. The SPR data suggested that most aptamers had high 
affinity for IFN-γ indicated by their sub-nanomolar KD. The lowest KD were 2.06E-
10 and 3.90E-10 for aptamers H12 and A9, respectively. The fast association (within 
10 min) and saturation after 60 min seen for aptamer H12 correlated to the low KD 
from the SPR data. 
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3.1  INTRODUCTION  
Secondary structures of aptamers have been shown to be a dominant element in 
determining their functionality (Jayasena, 1999). Aptamers assume their structures 
upon binding to their targets through a “lock and key” mechanism where they 
organise themselves to fit the target, showing great specificity and high affinity 
(Gold et al., 1995, Eaton et al., 1995). In addition, aptamers’ high discriminatory 
value allows them to bind their targets with dissociation constants in the sub-
nanomolar to picomolar range. Therefore, determining the binding kinetics of the 
aptamers is crucial in understanding their versatility (Jenison et al., 1994, Stoltenburg 
et al., 2007, Zimmermann et al., 2000). Assessing kinetics of aptamers allows us the 
understanding of how rapidly the aptamers and IFN-γ associate and also how soon 
the aptamers-IFN-γ complex dissociates. The sturdier the bond of the aptamer-
ligand, the lower the dissociation constant will be. Therefore, an ideal aptamer would 
have a fast association rate but a slow dissociation rate, resulting in a aptamer-ligand 
complex maintained for longer, then subsequently leading to a lower equilibrium 
dissociation constant (KD). In return, a low KD shows higher binding affinity 
(Stoltenburg et al., 2007). In the case of a point-of-care diagnostic, this phenomenon 
becomes crucial because the cascade of events (from introducing the biological 
sample to obtaining a read-out) will be a timed reaction.  
 
Moreover, to measure the binding affinity of aptamers to targets, binding studies 
using different assays have been employed over the years (Drolet et al., 1996, 
Cooper, 2003, Tang et al., 2007). This is a very important part of aptamer selection 
and is usually followed by studying aptamer-target interactions using techniques 
such as footprinting (Tahiri-Alaoui et al., 2002) and the three-dimensional binding 
structure is clarified through systems like nuclear magnetic resonance (NMR) 
spectroscopy (Santini et al., 2009, Baouendi et al., 2012, Foot et al., 2014). The 
information gathered from these assays assists in determining whether there is 
accurate binding between the ligand and target and if so, how much binding is 
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present. Regarding application in clinical medicine, the LOD becomes an important 
measure as it needs to fall within the biological range of diseased patients.  
 
This chapter assesses whether the candidate IFN-γ aptamers selected for 
characterisation have the properties of a promising detection molecule which can 
potentially be incorporated into different point-of-care tests for EPTB. Forty five 
ssDNA aptamers that significantly bound IFN-γ were isolated. Ten of the aptamers 
shown to have high binding affinity were initially selected. Of the ten, six with the 
most unique secondary strutures as determied by Mfold, and which were not found 
within the same cluster on the phylogenetic tree, were selected for further 
characterisation. Here, I employed ELONA and SPR to determine the binding 
affinity and dissociation constants (KD), of the respective six aptamers that 
significantly bound IFN. To further understand the mechanism of binding between 
the aptamers and IFN-γ, I studied the topologies of the secondary structures using 
different bioinformatics tools. The characterisation of aptamers was imperative 
because the aim of this thesis was to identify at least one aptamer that possesses all 
the necessary properties for the intended downstream application; in this case as 
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3.2  MATERIALS AND METHOD 
3.2.1 In silico analysis of selected aptamers using bioinformatic tools 
Aptamers form thermodynamic structures in order to bind to their targets with high 
affinity and specificity (Jayasena, 1999). I performed in silico analysis to identify 
hairpin loops, stems and bulge loops, which are properties of secondary structures 
known to improve their target affinity and specificity. A web-based software, Mfold 
(http://www.bioinfo.rpi.edu/applications/mfold), was used to predict secondary 
structures of the 6 selected IFN-γ aptamers. The algorithm calculates the minimum 
free energy between bases, also considering the stems, loops and bulges (Zuker, 
2003). Sequences for the selected aptamers (identified in the sequence alignment in 
Chapter 2, Section 2.3.2.1) were added in FASTA format as linear DNA. Secondary 
structure predictions were done at 37 °C (the physiological temperature of the body), 
1 M NaCl, 5% sub-optimality,  upper limit of 50 computed folding,  maximum 
interior/ bulge loop size of 30 base pair and maximum asymmetry of interior bulge 
loop of 30 base pairs. No limits were defined for the distance between base pairs. 
Predicted secondary structures were analysed carefully in order to identify any 
similarities in conformation within a particular aptamer, and between one aptamer 
and the next.  
 
Another common secondary structure conformation known to improve the stability 
of ssDNA aptamers is the G-quadruplex. The G-quadruplex, also known as a G-
quartet or G- tetrad, usually forms in the presence of a guanine (G)-rich nucleotide 
sequence in a square planar array. They stack themselves by means of strong 
Hoogsteen hydrogen bonds in that way stabilising the overall molecule (Gellert et al., 
1962). The Na+ and K+ cations are known to further stabilise the G-quadruplex at 
physiological temperatures and pH in vitro (Burge et al., 2006). The predictions of 
the G-quadruplex secondary structures were made computationally using a web-
based software Quadruplex forming G-Rich Sequences (QGRS) Mapper, 
http://bioinformatics.ramapo.edu/QGRS/ (Kikin et al., 2006). Predictions were done 
at 150 mM NaCl and 2 mM MgCl2, which are similar to the concentrations of these 
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cations in the 1 HMCKN binding buffer used during SELEX. Although this in 
silico analysis was a prediction it was necessary to mimic the conditions that were 
used to select the aptamers. The molecules are more likely to behave in the same way 
even if the environment is different.  
 
3.2.2 Limit of detection of IFN-γ aptamers 
3.2.2.1 Production of ssDNA aptamers  
This section describes the purification of DNA aptamers obtained during the SELEX, 
which were stored in E.coli vectors for later usage. Plasmid DNA was purified from 
stored glycerol stocks and ssDNA prepared. Overnight cultures were prepared and 
the plasmid DNA isolated using the QIAprep Spin Miniprep purification kit 
(QIAgen, Hilden Germany) as per the manufacturer’s instructions. 
 
The plasmid DNA was quantified, using the Nanodrop® ND-100 spectrophotometer 
v3.0.1 (Thermo Scientific, MA, USA), and used as template to perform a non-
mutagenic PCR (Chapter 2, Supplementary Table S2.8). Single-stranded DNA 
was subsequently prepared as described in Chapter 2, Section 2.2.1.4. This process 
produced insufficient ssDNA to carry out all the characterisation assays. Therefore, 
aptamers synthesised at large scale were purchased from Integrated DNA 
Technology Inc. (Integrated DNA Technology Inc., Iowa, USA). One batch of the 
aptamers was biotin-labelled at the 5′-end and the other was unlabelled. The 
synthesised aptamers were validated to ensure they were the correct size and 
contained no impurities. This was assessed on a 12% non-denaturing PAGE, stained 
with ethidium bromide for approximately 3 min and visualised, using ultraviolet 
(UV) trans-Illuminator GelDoc™ XR system (Biorad Laboratories, CA, USA).  
 
3.2.2.2 Limit of detection of IFN-γ 
In order to determine the lowest concentration of IFN-γ to perform functional assays, 
a titration from 100 µg/ml to 10 µg/ml was done. IFN-γ protein was diluted in 10 
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mM NaHCO3 to yield final concentrations of 100 µg/ml, 20 µg/ml, 10 µg/ml, and 2 
µg/ml. Fifty microliters of each dilution in triplicate was used to coat wells of a 96-
well microtitre plate (Corning, Adcock and Ingram, South Africa). The plate was 
incubated overnight at 4°C. The assay was carried out as described in Chapter 2, 
Section 2.2.3. However, a constant 300 nM of aptamer for each IFN-γ concentration 
was applied. The optical densities of aptamers at each IFN-γ concentration were 
compared to the IFN-γ-alone control (in absence of aptamer). The experiment was 
done in triplicate in two independent experiments (n=2).  
 
3.2.2.3 Determining the constant affinity of the aptamers for IFN-γ 
Using the IFN-γ concentration determined in the previous assay (Section 3.2.2.2), a 
2-fold dilution for each aptamer from 300 nM down to 18.75 nM, was performed. 
The assay was carried out as described in Chapter 2, Section 2.2.3, with a minor 
modification on day 2 where the aptamer was serially diluted 2-fold from 300 nM to 
yield 150 nM, 75 nM, 37.5 nM and 18.75 nM, and the IFN-γ concentration kept 
constant at 10 µg/ml. The optical densities of each aptamer at concentrations 150-
18.75 nM were compared to their respective at 300 nM. The experiment was done in 
triplicate in two independent experiments (n=2). 
 
3.2.3 Binding kinetics of aptamers 
3.2.3.1 A time course assay to determine the period required for IFN-γ-
aptamer complex formation 
In order to optimise the minimal time necessary for aptamers to bind IFN-γ, a time-
course assay was carried out using ELONA. The optimal concentration of IFN-γ, 10 
µg/ml, as determined by the assay described in Section 3.2.2.2 was used to coat the 
96-well microtitre plate (Corning, Adcock and Ingram, South Africa). Aptamers 
were prepared at 150 nM (the aptamer concentration determined in Section 3.2.2.3). 
Each aptamer was refolded prior to use as previously described in Chapter 2, 
Section 2.2.3. Fifty microliters of each aptamer was added onto the microtitre plate 
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(Corning, Adcock and Ingram, South Africa) at the following time-points: 120 min, 
60 min, 30 min, 20 min and 10 min. The remaining methodology was carried out as 
described in Chapter 2, Section 2.2.3. The optical density of each aptamer at time 
points 60-10 min was compared to its respective aptamer at 120 min. The experiment 
was done in triplicate in two independent experiments (n=2).  
 
3.2.3.2 Determining the equilibrium dissociation constant (KD) of selected 
aptamers 
The BIAcore uses surface plasmon resonance (SPR) technology, which calculates the 
association and dissociation constants (Ka and Kd), and thus calculates the 
equilibrium dissociation constant (KD) (Gonzalez-Fernandez et al., 2012). SPR is a 
label-free technology that responds to changes in the concentration of molecules at a 
sensor surface as molecules bind to or dissociate from the surface (Figure 3.1). 
Monitoring of the interacting molecules happens in real time. In order to determine 
the binding interaction, one molecule is immobilised on the surface of a gold-plated 
sensor chip using immobilisation chemistry e.g. amine coupling. The other binding 
molecule, which is in solution, is in a continuous flow at different concentrations 
usually from lowest to highest. The SPR response hereafter termed response units 
(RU) is directly proportional to the change in mass concentration close to the surface 
(Schasfoort and Tudos, 2008). 
 
3.2.3.2.1 Surface preparation for kinetic studies 
To study the binding kinetics of each aptamer, the BIAcore™ 3000 (Biacore, 
Uppsala, Sweden) was used. A CM5 chip (BIAcore, GE Healthcare, UK) containing 
carboxymethyl groups on the surface was activated through amine-coupling 
chemistry (Fischer, 2010). The chip was initially primed 3 times using running buffer 
(1 HMCKN) at a flowrate of 100 µl/min for 20 min. Priming removes preservatives 
and unwanted particles that may interfere with the immobilisation of IFN-γ. The chip 
needed to be wet in preparation for the IFN-γ and to moisten the polymer layer 
(Fischer, 2010). Additionally, the system was primed to ensure that all the residues 
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remaining in the tubules particularly protein (from previous experiments) was 
removed as it could interfere by being adsorbed to the surface of the chip during 
immobilisation of IFN-γ. Two flow cells of  the chip were activated using a 1:1 ratio 
of cross linkers, 0.2 M 1-Ethyl-3-(3-dimehylaminopropyl) carbodiimide 
hydrochloride (EDC) and 0.5 M N-Hydroxysuccinimide (NHS) (BIAcore, GE 
Healthcare, UK). IFN-γ (50 μg/ml) was immobilised on 1 flow cell and activated 
with 10 mM acetate buffer of the appropriate pH for the protein (in this case pH 4.0). 
To block any remaining activated carboxymethyl groups, 1 M Ethanolamine-
hydrochloride-NaOH (pH 8.5) (BIAcore GE Healthcare, UK) was injected over both 
flow cells. The one flow cell where no protein was immobilised served as a reference 
blank. The flow rate of 10 μl/min was used and 7 min contact time was allowed. 
 
3.2.3.2.2 Binding kinetic analysis of IFN-γ aptamers 
To measure the binding kinetics, aptamers were prepared through serial dilution at 
concentrations 0.8 nM, 4.6 nM, 27.8 nM, 166.7 nM, and 1 µM using 1 HMCKN 
buffer (20 mM Hepes, 2 mM MgCl2, 2 mM CaCl2, 2 mM KCl and 150mM NaCl, 
pH 7.4). Two blanks (without aptamer) were included, one before injection of the 
lowest concentration and one after injection of the highest concentration to ensure 
that there would be a suitable blank to normalise the data during each run. 1 
HMCKN buffer (running buffer) was filtered through a 0.22 µm filter and de-gassed 
before use.  Filtering and de-gassing the buffer was essential as any small air bubbles 
or any other small particles found could potentially cause disturbances and 
negatively affect the experiment.  For example, air spikes (seen on the sensorgram) 
are attributed to the presence of air bubbles in an inadequately or non-degassed 
running buffer. Aptamers were treated by heating at 95°C for 3 min, immediately 
cooling on ice for 5 min and left to reach room temperature for 5 min prior to use. 
The aptamer solutions were centrifuged before being loaded on the instrument as an 
extra precaution against bubbles. Aptamers were injected over the protein from the 
lowest to the highest concentration in triplicate across both flow cells at a flow rate 
of 50 μl/min allowing 2 min of contact time. The aptamers were allowed to 
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dissociate over 10 min. The surface was regenerated after each cycle, using 20 mM 
NaOH as a single injection at 30 μl/minute for 30 sec. A pre-needle dip between 
injections was performed to control for cross contamination. One of the blanks was 
used to normalise the data. The reference blank was subtracted prior to analysis.  
 
 
Figure 3.1: A schematic representation of the surface plasmon resonance (SPR) technology. 
SPR measures the polarised light at an angle when the protein binds the aptamer and that measurement 
is referred to as a RU. A protein is immobilised on the sensor chip with a plated gold film. The aptamer 
is injected over the immobilised protein and the signal response is measured in real time (Cooper, 2003). 
 
 
3.2.4  Statistical analysis 
3.2.4.1 ELONA 
Data was analysed using GraphPad Prism version 5.0 software (GraphPad Prism 
Software Inc. CA, USA), where the statistical analysis was performed by one-way of 
variance (ANOVA) followed by Bonferonni as a post-hoc test. One-way ANOVA 
was used to compare different groups (IFN-γ concentrations, aptamer concentrations 
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and/or time points). Data sets are presented as the mean ± SE. For all tests, data with 
a p-value of ≤0.05 was considered statistically significant. Each experiment was 
performed at least twice to ensure reproducibility.  
 
3.2.4.2 SPR  
The true values of aptamer binding to IFN-γ were subtracted from the blank 
reference followed by the analysis, which was done assuming a 1:1 Langmuir model, 
using BiaEvaluation v4.1 Software (BIAcore, GE Healthcare, UK). The model was 
used to determine the association rate (Ka), dissociation rate (Kd) and the equilibrium 
dissociation constant (KD). A simultaneous fit for Ka/Kd was performed to calculate 
the KD. Analysed data was then exported to GraphPad Prism version 5.0 software 
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3.3  RESULTS 
3.3.1 Structural characterisation of selected aptamers 
Predictions of the structures were done using the Mfold algorithm. Each aptamer had 
multiple secondary structure predictions (up to 6 secondary structures). A 
representative of each aptamer is shown in Figure 3.2, which is the structure 
predicted to be the most stable (as it had the lowest minimum free energy). The 
minimum free energies (ΔG) are shown in Table 3.1. The remaining secondary 
structures together with the minimum free energies can be found in Appendix 3.1. 
The primer sequences are shown in arrows on the structures where blue arrows 
represent the forward primer and red arrows represent the reverse primer. When 
structures were studied closely, primer sequences of most aptamers were found 
within the bulge-loop with the exception of aptamers A9 and B2, where the forward 
primer formed part of a stem hairpin loop, and partially so for aptamer B4.  
 
The nucleotides shown to be in contact with the target are usually found within the 
stem hairpin loops and are usually 10-15 bases long  (Gold et al., 2005). Part of the 
sequence involved in binding was predicted to be within the 49mer motif or random 
region of the aptamers. All predicted structures for each aptamer had a similar stem 
hairpin loop with variable lengths of stems, which is highlighted by a black box on 
the structure (Figure 3.2).  This is part of 49mer motif, predicted as the portion 
which interacts with the target as it was observed across all possible secondary 
structures the aptamer could assume upon binding with its specific target. Aptamer 
H12 had the least possible structures (it could assume only 2) and contained the 
longest stem.  A low minimum free energy (ΔG=-1.88) was noted for H12, which 
made it a good candidate for downstream applications as it appeared to be the most 
stable. Another aptamer forming a long stem was aptamer B4. However, the 
minimum free energy was not as low (ΔG = -4.81) as H12. The lowest minimum free 
energy for B4 was ΔG= -4.79, but the structure for this aptamer was not as defined as 
the rest and thus, not shown as the representative (see Appendix 3.1). The remaining 
aptamers A1, A2, A9 and B2 had fairly short stems forming the stem hairpin loops 
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with A9 and A2 having the shortest. Furthermore, aptamers A9 and B2 had the 
lowest free energies amongst all aptamers, which were ΔG =-0.97 and ΔG =-0.94, 
respectively. Even though aptamer A1 and B4 had slightly increased minimum free 
energies, ΔG =-5.59 and ΔG =-4.81, they were predicted to have the ability to form a 
G-quadruplex, which is elaborated further in Section 3.3.2.  
 
 
Figure 3.2: Representative secondary structures of the selected IFN-γ aptamers as determined 
by Mfold.  GQRS Mapper was used to determined G-quadruplex structures. 
The ΔG represents the minimum free energy of each aptamer. Each aptamer had between 2 and 6 
possible secondary structures, however, only a representative of each is shown. The forward primer 
sequence (bases 1-21) is shown by the blue arrows and the reverse primer (bases 71-90) are shown by 
the red arrows. Common stem loops within each aptamer are depicted using solid black boxes. 
According to the algorithm used by QGRS mapper software, aptamers A1 and B4 could form G-
quadruplexes. The G-bases (in doubles), commonly referred to as G-doublets, which are suggested to 
take part in forming the G-quadruplex are shown in green boxes. These G-bases had the highest 
probability as shown by their G-scores, which were 17 and 18 for A1 and B4, respectively. 
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Table 3.1: The number and minimum free energy of possible secondary strutcures for 
each aptamer  
  
Aptamer ID No. of predicted 
structures 
Minimum free energy (ΔG) in kcal/mol 
A1 5 −5.59, −5.86, −6.25, −5.72, −5.77 
A2 5 −1.20, −2.00, −1.93, −1.64, −1.85 
A9 4  −0.97, −1.13, −1.28, −1.78 
B2 5 −0.94, −1.09, −1.33, −1.55, −1.84 
B4 6 −4.81, −4.91, −5.19, −5.24, −5.72, −4.79 
H12 2 −1.88, −2.13 
 
 
3.3.2 Aptamers A1 and B4 have the ability to form a G-quadruplex 
Aptamers were evaluated for their ability to form G-quadruplex structures, using 
QGRS mapper. Two aptamers A1 and B4 had the ability to form a G-quadruplex 
with G-scores of 18 and 17, respectively (Table 3.2). The G-score, defined as the 
probability of a molecule to from a G-quadruplex, is calculated based on the size and 
length of the loops formed by the molecule and the number of guanines present or 
responsible for forming the G-quadruplex. The scores are dependent on the user’s 
selected maximum QGRS length. The maximum length was 30 nucleotides, which 
was the default setting used for the analysis. Therefore, the higher the G-score of an 
aptamer, the more stable it is predicted to be. The highest G-score, using this default 
setting of 30 nucleotides in length, is 105 in which case a sequence will comprise of 
95% of guanine bases. The number of bases responsible for forming the G-
quadruplex for aptamer B4 was 24 nucleotides (nt), starting at position 36 on the 
sequence of the 90nt long aptamer (the full aptamer sequence is shown in the far 
right column of Table 3.2). Aptamer A1 had 22nt forming the structure, starting at 
position 23 of the full aptamer sequence. To further classify the topology of  
aptamers B4 and A1, the number and position of the G-tetrads involved in forming 
the structure was determined (Burge et al., 2006). Both were found to be 
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unimolecular  and contained 2 G-tetrads separated by arbitrary bases in unequal 
length or composition, which form the loops or gaps (Figure 3.2). Structures 
comprising a higher number of G-tetrads (four) have been shown to be more stable 
(Kikin et al., 2006). The G-bases predicted to form the G-quadruplex are further 
annotated on the secondary structures of the aptamers, using green boxes (Figure 
3.2). The remaining aptamers A2, B2, A9 and H12 did not have the ability to form 
the G-quadruplex.  
 








GQRS G-score Sequence 
 




















3.3.3 Validation of chemically synthesised aptamers to be used for 
characterisation assays 
During the production of ssDNA aptamers by the lambda exonuclease method 
(Chapter 2, Section 2.3.2.1), it was important that the ssDNA produced be validated 
for the presence of impurities and contaminants. Also, the correct size had to be 
confirmed using a low range DNA marker. Additionally, synthesised aptamers were 
similarly validated (Figure 3.3). Two batches of synthesised aptamers were obtained 
although only the unlabelled aptamers are shown here (Figure 3.3). All aptamers 
were found to be the expected size of 90bp. Aptamer A1 showed multiple bands, 
which was an indication of the multiple conformations it could adopt. It seemed like 
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a high concentration was loaded onto the gel for each aptamer, which was indicated 




Figure 3.3: Validation of the synthesised aptamers on a 12% non-denaturing PAGE. 
Lyophilised aptamer stocks were re-suspended in ddH2O to a yield a final concentration of 100 µM and 
then diluted to 100 nM. Synthesised aptamers were run on gel to confirm the correct size of the aptamers 
and to ensure there were no contaminants present. The gel was run for 1 hour at 100 V and stained with 
ethidium bromide for approximately 3 min. Lane 1: DNA low range molecular marker, lanes 2-7: 
Aptamers A1, A2, A9, B2, B4 and H12, respectively. Aptamers were estimated to be around the 
expected size of 90 bp. 
 
 
3.3.4 Affinity characterisation of IFN-γ aptamers 
3.3.4.1 The limit of detection of IFN-γ  
To determine the minimum concentration of IFN-γ that could be accurately detected 
by the respective aptamers, a limit of detection experiment was performed. The 
detection limit result contributed to optimising subsequent assays.  A dilution 
gradient ranging from 100 µg/ml to 2 µg/ml of IFN-γ was tested using biotin labelled 
aptamers at a final concentration of 300 nM (Figure 3.4). All aptamers, A1, A2, A9, 
B2, B4 and H12, bound significantly  to IFN-γ (p≤0.001) at concentrations of 100 
µg/ml, 20 µg/ml and 10 µg/ml (Figure 3.4: B-C).  At a concentration 2 µg/ml of 
IFN-γ, OD values of aptamers A1, A2, A9 and B4 were undetectable and aptamers 
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B2 and H12 did not bind significantly (Figure 3.4: D). The degree at which the 
aptamers bound to IFN-γ was dependent on its concentration. The minimum 
concentration of IFN-γ that all the aptamers could significantly bind was 10 µg/ml. 
Therefore, this concentration was used in all subsequent assays 
.  


















































































































































































Figure 3.4: Binding of aptamers to IFN-γ. 
Aptamers were tested for the lowest concentration of IFN-γ they could detect by ELONA. Varying 
concentrations of IFN-γ were tested: 100 µg/ml, 20 µg/ml, 10 µg/ml and 2 µg/ml (bar graphs A-D). A 
blank (buffer only) was included in each experiment and used to subtract the background noise. The 
binding of aptamers were compared to that of the IFN-γ-alone (absence of aptamer) control using 1-
way ANOVA with Bonferroni’s post-test, where significant differences were denoted by **=p≤0.01 
and ***=p≤0.001.. Data presented are for two independent experiments (n=2) each done in triplicate. 
Error bars denote mean ± SE. 
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3.3.4.2 Determination of the minimum concentration of aptamers that bound the 
minimum concentration of IFN-γ 
To determine the minimum and saturation concentrations of the six aptamers that 
could significantly bind the minimum concentration (10 µg/ml) of IFN-γ determined 
above, the aptamers were serially diluted and used in ELONA.   
  
A significant reduction in binding (p≤0.001) was observed at concentrations 18.75-
150 nM for aptamer A1 (Figure 3.5: A), when compared to binding at 300 nM, 
which suggested that as the concentration was decreased, the binding was also 
significantly reduced. A similar pattern was observed for aptamers B4 (Figure 3-5: 
E) and B2 (Figure 3.5: D), where a reduction in binding was seen from a 
concentration of 75 nM. Significant differences in binding for aptamers B4 (300 nM 
vs 75 nM and 37.5 nM (p≤0.05); 300 nM vs 18.75 nM (p≤0.001)), B2 (300 nM vs. 
37nM (p≤0.05); 300 nM vs. 18.75 nM (p≤0.01)), and A2 (300 nM vs. 18.75 nM 
(p≤0.05)) were observed. No significant differences in binding were seen for 
aptamers A9 (Figure 3.5: C) and H12 (Figure 3.5: F). Aptamers A9 and H12 
maintained the same binding affinity, regardless of a reduction in aptamer 
concentration, which indicated that these aptamers possibly reach saturation at 18.75 
nM in the presence of 10 µg/ml of IFN-γ. No difference in binding was observed at 
300 nM vs. 150 nM for all aptamers with the exception of aptamer A1, which 
suggested that A1 could be reaching saturation at 150 nM. However, aptamers H12, 
B2, A9 and A2 reached saturation at 75 nM, as no difference in binding was 
observed when compared to 300 nM. The data proposes that aptamers A1, B2 and 
B4 bound IFN-γ in a concentration-dependent manner and a concentration of no 

































































































































































































































Figure 3.5: Aptamer binding to constant IFN-γ concentration of 10 µg/ml. 
Aptamers were tested in a 2-fold serial dilution at 300 nM, 150 nM, 75 nM, 37.5 nM and 18.75 nM, 
using a constant concentration of IFN-γ of 10 µg/ml. Following the addition of the aptamers at different 
concentrations, the rest of the parameters were kept constant throughout the assay. The binding of 
aptamers from 150-18.75 nM was compared to the binding of each aptamer at 300 nM using 1-way 
ANOVA with Bonferroni’s post-test, where significant differences were denoted by *=p≤0.05, 
**=p≤0.01 and ***=p≤0.001. Data presented are for two independent experiments   (n=2) each done in 
triplicate. Error bars denote mean ± SE. 
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3.3.5 Binding kinetic studies of selected IFN-γ aptamers 
3.3.5.1 A time-course assay to determine highest binding of aptamers 
To determine the time necessary to reach the highest binding of aptamers to IFN-γ, a 
time-course assay was performed, using OD and time via ELONA. Additionally, the 
method measured the stability of the aptamer-IFN-γ complex over time. Binding of 
aptamers to IFN-γ was measured at time-points 10, 20, 30, 60 and 120 min. Aptamer 
and IFN-γ concentrations were kept constant at 150 nM and 10 µg/ml, respectively 
(Figure 3.6). From the previous data (Section 3.3.4.2), it seemed possible that some 
aptamers (H12, A9, B2 and A2) could be reaching saturation at 75 nM. In order to 
ensure complete saturation, aptamers were tested at 150 nM.  
 
Aptamers A1 and A9 bound IFN-γ in a time-dependent manner. When binding at 60 
min was compared to the binding at 120 min for aptamers H12, A1 and B2, no 
difference in binding was observed, although a significant reduction was seen when 
compared at 10-30 min (Figure 3.6). For A1 at 120 min vs. 10, 20 min, p≤0.01 and 
120 vs. 30 min, p≤0.05) (Figure 3.6: A); B2 120 min vs. 10, 20 & 30 min, p≤0.01 
(Figure 3-6: D) and H12 120 min vs. 10, 30 min, p≤0.001 and 120 min vs. 20 min, 
p≤0.01 (Figure 3.6: F). The fact that there was no significant difference at 120 vs. 60 
min could be indicative of a slow dissociation rate of the aptamer-IFN-γ complex and 
the aptamers were thus reaching a plateau at 60 min. The observation suggests that  
the KD for these aptamers should be low, at least in the sub-nanomolar range 
(Kulbachinskiy, 2007). Also observed was a significant reduction in binding at time-
points 60 min down to 10 min for aptamers A2 (p≤0.001) (Figure 3.6: B) and A9 
(p≤0.001) (Figure 3.6: C); B4 from 10-30 min (p≤0.001) and also at 60 min 
(p≤0.05) (Figure 3.6: E), which showed a fast association which kept constant over 
time.  A 1-fold reduction was seen for aptamer A2, which could be attributed to a 
fast association, followed by a fast dissociation, leading to instability of the aptamer-
IFN-γ complex. This phenomenon was predominantly associated with aptamer B2, 
where the molecules quickly came together (fast association rate), but seemed to 
decrease slightly in binding when incubated for longer. In contrast, aptamer H12 
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seemed to stay bound to IFN-γ as time progressed, except for a slight decrease when 
incubated from 20-30 min (120 vs. 10 min (p≤0.001), 120 vs. 20min (p≤0.01), 120 
vs. 30min (p≤0.001) (Figure 3.6: F). Aptamers that have a slower dissociation rate, 
which is usually equivalent to a lower KD, are preferred. The reason is that it is an 
indication of the stability of a complex over a longer time period (Jayasena, 1999). 
From this data, it seems that aptamers H12, A1 and A9 could be good candidates for 
downstream applications that require one of the molecules to be immobilised on a 
solid surface. This is further supported by the fast association rate of the aptamers to 
IFN-γ (in 10 min) and the continued strong bond, which increased over time. Taken 
together, these results showed that 60 min incubation was sufficient to ensure 
complete binding of aptamer to IFN-γ.  
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Aptamer A1
















































































































































































Figure 2.6: Assay to determine how OD450 changes over time at aptamer concentration of 150 
nM. 
Aptamers at a concentration of 150 nM were incubated at different time points: 120 min, 60 min, 30 
min, 20 min and 10 min. Binding of aptamers at variable times was compared to their respective aptamer 
at 120 min using 1-way ANOVA with Bonferroni’s post-test, where significant differences were 
denoted by *=p≤0.05, **=p≤0.01 and ***=p≤0.001. Data are for two independent experiments (n=2) 
each done in triplicate. Error bars denote mean ± SE. 
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3.3.5.2 Surface preparation for determination of kinetics of selected aptamers 
To further characterise the aptamer- IFN-γ complexes I used a Biacore 3000. I 
optimised the immobilisation of IFN-γ using 10 mM acetate buffer at pH 4.0, which 
was the optimal pH to obtain the highest possible response units (RU). The 
immobilised IFN-γ bound at 5500 RU at pH 4.0 determined during pH scouting 
(Figure 3.7). A sensorgram, showing the different stages in surface preparation is 
shown below. In order to prepare the CM5 sensor chip for kinetic measurements, the 
surface had to be activated with EDC: NHS before immobilising the IFN-γ. All sites 
during activation, which do not have IFN-γ bound to them, were blocked with 
ethanolamine, which creates an even surface and prevents protein edging. 
 
 
Figure 3.7: A sensorgram showing the immobilisation of IFN-γ on a CM5 sensor chip prior to 
kinetic analysis. 
IFN-γ protein was immobilised using amine coupling chemistry. The chip’s carboxyl groups were 
activated through EDC: NHS, followed by immobilisation of 50 µg/ml of IFN-γ. Activated carboxyl 
groups sites which had no IFN-γ bound were then blocked with ethanolamine. The surface was 
regenerated and unbound IFN-γ was removed with 20 mM NaOH. The final immobilised IFN-γ was 
approximately 5500 RU. The control flow cell was”no protein” control, where no IFN-γ was 
immobilised to the surface. 
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3.3.5.3 Determination of the binding kinetics of selected aptamers 
The KD was determined for each aptamer (Figure 3.8) and a summary of the kinetic 
parameters is outlined in Table 3.3. The kinetics of the individual aptamers revealed 
that most of the aptamer bound the target within the low nanomolar to picomolar 
range (Figure 3.8). The kinetic assessment procedure determines association and 
dissociation constants by fitting the experimental data to a 1:1 molecule interaction 
model (Langmuir) between molecule A and molecule B. Therefore, for purpose of 
clarification, Ka is defined as the association rate constant (M-1s-1), Kd is the 
dissociation rate constant (s-1) and KD is the equilibrium dissociation constant (M), 
where at equilibrium: association = dissociation. 
 
Aptamers with the lowest KD were A9 and H12 at 3.90E-10 and 2.06E-10, 
respectively. Both aptamers had a rapid association rate as indicated by their Ka at 
2.56E+5 and 2.32E+5, respectively (Table 3.3). Aptamers A1, A2, B2 and B4 had a 
KD of 5.39E-9, 6.28E-8, 1.94E-8 and 8.61E-9, respectively. Also noted was that A1, 
A2, B2 and B4 had a Ka 10-fold higher than A9 and H12 (Table 3.3). Aptamer A1 
also had the ability to form a G-quadruplex structure (see Section 3.3.2), which 
would play a significant role in stabilizing the overall aptamer-IFN-γ complex.  
Thus, in spite of aptamers A9 and H12 being favoured due to their low KD, A1 was 
chosen to be characterised further as it had a low KD, and the ability to forma  G-
quadraplex, which are the two characteristics of utmost importance in applications 
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Figure 3.8: Kinetic analysis of aptamer binding to IFN-γ. 
SPR technology was used to measure the association and dissociation constant rates and equilibrium 
dissociation constant of each IFN-γ aptamer. Recombinant IFN-γ was immobilised on a CM5 chip and 
each aptamer was exposed to the immobilised IFN-γ at varying concentration, ranging from 0.13 nM to 
1000 nM. The aptamer concentration is shown on the top right corner of each graph and the KD is shown 
at the bottom right corner. The aptamers and the IFN-γ were allowed 7 min contact time before 
dissociation. To calculate and determine the equilibrium dissociation constant using the association and 
dissociation constant rates, a 1:1 Langmuir model was assumed using the BIAevaluation v4.1 software. 
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A1 3.75E+4 2.02E-4 5.39E-9 
A2 3.77E+4 2.35E-3 6.24E-8 
A9 2.56E+5 9.57E-5 3.90E-10 
B2 5.53E+4 1.07E-3 1.94E-8 
B4 6.05E+4 5.21E-4 8.61E-9 
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3.4  DISCUSSION 
The previous chapter described the selection and identification of 45 aptamers that 
significantly bound IFN-γ. In this chapter, I further characterised the six selected 
aptamers using bioinformatics tools and binding studies.  The key findings in this 
chapter were: (i) the aptamers were predicted to form distinct secondary structures 
and a G-quadruplex; (ii) The LOD of IFN-γ was 10 µg/ml for all the aptamers; (iii) 
Aptamers had sub-nanomolar-picomolar KD.  
 
Subsequent binding studies of the individual aptamers were carried out to determine 
their affinity to IFN-γ as their downstream application is dependent upon this 
(Stoltenburg et al., 2007). Firstly, to understand the mechanism of binding and 
identifying the nucleotides possibly responsible for the specific binding, 
bioinformatic software (Mfold and QGRS Mapper) were used. Each aptamer was 
predicted to have multiple secondary structures and the minimum free energy ranged 
from Δ-0.94 to Δ-6.25 kcal/mol.  
 
The aptamers shared structural similarities in that they all contained 2-3 hairpin stem 
loops within a bigger bulge loop per structure, where aptamer H12 was found to have 
the longest hairpin stem loop. Within the 2-3 stem hairpin loops, one was common in 
all predicted derivatives of each aptamer.  This hairpin stem loop is set to interact 
directly with the target thereby enhancing its specificity and high affinity (Jayasena, 
1999). The motif was found within the stem hairpin loops, which is apparently where 
the binding happens as hypothesised (Gold et al., 1995). Gold showed that the full 
length aptamer had three functional regions, with only about 18-20 bases of the 
aptamer coming into contact with the target (Gold et al., 1995). Therefore, a portion 
of the 49mer motif of the IFN-γ aptamers was involved in this regard. Additionally, a 
small portion of the reverse primers of aptamers A2 and A9 were found to form a 
stem hairpin loop. The finding was unexpected as the primers are unlikely to interact 
with the target during binding. Furthermore, the ability of aptamers B4 and A1 to 
form a G-quadruplex structure confers their increased stability.  Although G-
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quadruplex structures have been shown to improve stability of aptamers, and a few 
have been developed over the years, the thrombin-binding aptamer (TBA) remains 
the only well-characterised G-quadruplex aptamer (Kelly et al., 1996). Also, 
characteristics of aptamers being able to fold into 3D structures and fold pockets 
upon binding with their targets has become the foundation of developing biosensors 
(Zhou et al., 2010, Cao and Chen, 2011, O'Sullivan, 2002). Moreover, none of the 
previously reported IFN-γ aptamers were able to form G-quadruplexes 
(Balasubramanian et al., 1998, Cao et al., 2014). 
 
To further characterise the six selected aptamers, their binding affinity to IFN-γ was 
determined. The lowest detection limit using ELONA was 10 µg/ml. The biological 
range of IFN-γ in the pleural fluid is estimated to be in picogram concentrations. 
Therefore, although the LOD was low, the sensitivity of the aptamers can be 
improved. For example, the aptamers can be conjugated to nanomaterials such as 
gold nanoparticles to enhance the sensitivity of the assay as it was demonstrated by. 
Peng and co-workers (2013) using a traditional ELISA. In this study the sensitivity 
was increased almost 20 times that they could detect as low as 5.6 pg/ml of 7-
aminonitrazepam (7-ANZP), which is a primary urinary metabolite of nitazepam 
(Peng et al., 2013). Despite our reported low sensitivity, similar concentrations (5-10 
µg/ml) have been used to conduct binding studies using the ELONA platform (Tang 
et al., 2014, Martín et al., 2013). In addition, Martin and co-workers (2013) also 
reported that their aptamers bound Leishmania protein in a concentration-dependent 
manner, consistent to our findings. Aptamers A9 and H12, in particular, were 
depicted as good candidates as no differences in binding were observed at the 
variable concentrations of aptamer. These data suggest that they reached saturation at 
a low concentration, thus showing a desirable property for an inexpensive point-of-
care test.  
 
To further study the stability of the aptamer-IFN-γ complexes, binding kinetic 
studies were undertaken. All aptamers bound IFN-γ with dissociation constants in the 
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low nanomolar range, in particular aptamers A9 and H12, had a KD in the picomolar 
range, potentially making them ideal molecules for diagnostic applications. This was 
further supported by their low minimum free energy for their secondary structures. 
These reported KD values are in agreement with previous results achieved for other 
TB aptamers (Balasubramanian et al., 1998, Liu et al., 2010, Rotherham et al., 2012, 
Ngubane et al., 2014, Tang et al., 2014).  Examples include the CSIR 2.19 DNA 
aptamer to ESAT6-CFP10, which had a KD=1.6±0.5 nM (Rotherham et al., 2012), 
EsxG RNA aptamer at KD=8.04±1.90 nM (Ngubane et al., 2014), DNA aptamer for 
IFN-γ at KD=3.11±0.84 nM (Balasubramanian et al., 1998, Liu et al., 2010). This 
data therefore concurs well with reports that aptamers appear to have binding 
properties that compare well with antibodies, which also have KD in the low 
nanomolar range (Sikarwar et al., 2014, Liu et al., 2014). The low KD of the aptamers 
allows them to compete with their antibody counterparts. Perhaps the two molecules 
(aptamer and antibody) could even be paired together to increase the sensitivity of 
the IFN-γ aptamers. Although aptamers A9 and H12 did not form G-quadruplex 
structures, binding kinetics data suggest that they are also good candidates for use in 
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3.5  CONCLUSION 
I have identified six ssDNA aptamers that bind IFN-γ with high affinity. The results 
demonstrate that these selected aptamers can detect IFN-γ on ELONA and SPR 
platforms. Moreover, the secondary structures correlated with the findings of high 
binding affinities and enhanced stability as denoted by the long stem hairpin loop. 
Binding of the aptamers was in the sub-nanomolar range (109-1010 M), directly 
showing that these aptamers had high affinity for IFN-γ. The findings suggest that 
these aptamers can supplement or substitute antibodies (where antibodies have failed 
on their own). Notwithstanding,  the LOD shown in this study IFN-γ suggest that 
these aptamers in their current form are not desirable for developing a POC test for 
EPTB, because IFN-γ is found in picogram concentration in clinical samples. This 
limitation can be overcome by conjugating the aptamers to different nanomaterials as 
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The high degree of specificity often seen in aptamers is a result of the selectivity in 
SELEX, which eliminates sequences that bind closely related analogues of the target. In 
this chapter, the six aptamers were further characterised to determine if they are specific 
to IFN-γ. In addition, the binding of the aptamers to IFN-γ in the presence of an anti-
IFN-γ antibody was evaluated. Folding studies were also used to elucidate the 
importance of aptamer re-folding prior to use in assays.  
 
One aptamer, A1, with desirable properties such as high affinity to IFN-γ and predicated 
stable secondary structure that form G-quadruplex, was truncated into three derivatives: 
a 49mer, a 36mer and a 29mer. Their binding affinities were determined and compared 
to the full length aptamer (90mer). All six full length aptamers showed high specificity 
for IFN-γ (p≤0.001). Data from the indirect ELONA using anti-IFN-γ CD66 suggested 
that aptamer H12 could be used in conjunction with an antibody. In addition, folding 
studies revealed that the binding of aptamer A1 was significantly increased (p≤0.01) 
when used without being re-folded. Binding for the truncated derivatives of A-36mer 
and 29mer was the same as that of the 90mer. Although the 36mer and 29mer had 
increased affinity for IFN-γ at 150 nM, only the 49mer truncated derivative was able to 
detect IFN-γ (10 µg/ml) at a reduced concentration of 18.75 nM. The binding kinetics of 
the 29mer were performed, and these revealed a 10-fold increment in KD when 
compared to the 90mer. The KD for the 90mer and 29mer were 5.39E-9 and 1.02E-10, 
respectively. Thus, the aptamers described in this study displayed high specificity for 
IFN-γ and also demonstrated their capability of being paired with an antibody to develop 
a sandwich assay. Moreover, truncated derivatives for aptamer A1 maintained the same 
binding affinity to IFN-γ, comparable to the parental molecule.  
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4.1 INTRODUCTION 
A pre-requisite for a reliable diagnostic test is the ability of the detection molecule to 
accurately measure the target in the sample. Aptamers have been shown to have these 
qualities by binding their targets with high affinity and specificity (Eaton et al., 1995, 
Gold et al., 1995). In this chapter, the six selected aptamers were further characterised to 
determine their functionality for potential development as diagnostic reagents for EPTB. 
Specifically, their specificities to IFN-γ and competition with anti-IFN-γ antibody were 
respectively determined. Moreover, I also truncated aptamer A1 and determined binding 
kinetics of its derivatives to IFN-γ.  
 
Although aptamers have been reported to rival antibodies in diagnostics application 
(Jayasena, 1999), antibodies remain widely used in clinical medicine (Ruigrok et al., 
2011). Antibody-based assays like ELISA continue to be the most frequently used tests 
in routine diagnostics. This is mainly due to their ability to recognise their targets with 
high specificity and affinity. This has been the case for decades despite their drawbacks. 
For instance, their large and complex structure makes them susceptible to degradation 
and denaturation. They also have limited stability and modifying them results in loss of 
sensitivity (Mairal et al., 2008). Their large size (±150 kDa) is also limiting. However, 
they have been shown to partner well with aptamers (Drolet et al., 1996). Thus the 
combination of antibodies and aptamers warrants further investigation in developing 
more robust POC tests. 
 
Aptamers, in contrast, have more attractive qualities. Their size (5-20 kDa), stability and 
structural properties makes them preferred over their counterparts especially in 
platforms like biosensors (Jhaveri and Ellington, 2001). Their ability to change structure 
upon binding with target means they can be used to design sensors that are similar to 
molecular beacons (Patel et al., 1997, Wang et al., 2005, Yamamoto et al., 2000, Zhou et 
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al., 2010, Nutiu and Li, 2005, Nutiu and Li, 2004). Their amenability to modification 
without compromising their affinity and specificity further make them desirable 
molecules for diagnostic applications. Furthermore, their size allows them to be 
immobilised in high densities therefore warranting their reusability (Mao et al., 2010). 
This therefore indicates that one can now picture aptamers as equivalent, and in some 
ways superior, to antibodies in diagnostics (O'Sullivan, 2002). Likewise, more 
affordable, rapid and robust POCs can be developed in order to control the TB endemic, 
especially in developing countries. 
 
The nature of most clinical samples of EPTB, particularly pleural fluid samples is 
known to be heterogeneous. This is the first major challenge of diagnostics when using 
pleural fluid even more so for a POC test where one would not be subjected to pre-
treating the sample. Furthermore, pleural fluid removed from patients via a pleural tap 
can sometimes appear bloody or milky, which increases the heterogeneity of the sample 
due to the presence of red blood cells. The second major challenge is the concentration 
of IFN-γ found in pleural fluid. Recent work in our laboratory has shown that IFN-γ is 
available in trace amount  (10-250 pg/ml) in pleural fluid (Meldau et al., 2014). Due to 
other larger proteins present, which are also present in high concentrations, IFN γ is not 
easily detectable as it is masked by these proteins. For example, albumin is a 150 kDa 
protein, which is found abundantly in pleural fluid and almost 10-fold larger than IFN-γ, 
which is only 17 kDa.  
 
In this chapter, I therefore tested the specificity of aptamers to IFN-γ in relation to other 
proteins abundantly found in the pleural fluid such as albumin. I also evaluated the 
binding of aptamers to IFN γ in the presence of an anti- IFN-γ antibody. To further 
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4.2 MATERIALS AND METHODS 
All the aptamer preparations, ELONA and methods used to determine the optical density 
are as previously described in Chapter 2, Section 2.2.3, unless stated otherwise. 
 
4.2.1 Aptamer specificity testing 
Although aptamers can be specific in laboratory settings, when placed in pleural fluid it 
can be problematic to attain the same specificity due to the reasons stated above. 
Therefore to test for specificity, mycobacterial and non-mycobacterial molecules were 
used. The molecules were selected carefully so that they included some proteins present 
in the pleural fluid as well as other known mycobacterial proteins. The tested proteins 
included were diverse and are listed in Table 4.1. Interleukin 4 (IL-4) and pure protein 
derivative of tuberculin (PPD) were donated by Mr Anil Pooran and Dr Malika Davids 
from the Department of Medicine, University of Cape Town. Proteins were tested at a 
concentration of 10 µg/ml and IFN-γ was included as a positive control. The assay was 
carried out as previously described in Chapter 2, Section 2.2.3. 
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Table 4.1: Investigated proteins and molecules and controls used for specificity testing 
 
Proteins/molecules Quantity Positive control Negative Controls 
 
Interleukin 4 (IL-4) 
 








Pure protein derivative of 
tuberculin (PPD) 
 




 Coating buffer only 
Glucose  Wash buffer only 
(TBS) 
Casein  Block buffer (10% fat-
free milk solution 





4.2.2 Aptamer-Antibody sandwich ELONA assay 
A sandwich ELISA has been shown to improve sensitivity of the molecule being 
detected, hence their widespread use in clinical diagnostics (Engvall and Perlmann, 
1971). A sandwich ELISA includes capture and detection molecules, respectively. The 
capture molecule is usually not labelled, while the detection molecule is labelled to 
allow visualisation and quantification of the reaction. Streptavidin- horseradish 
peroxidase (HRP) is the most widely used detection agent in ELISA platforms. In this 
chapter, a sandwich ELONA was optimized using a biotinylated aptamers and a capture 
anti-IFN-γ monoclonal antibody (donated by Antrum Biotechnologies Inc., South 
Africa). The two anti-IFN-γ monoclonal antibodies tested were CD119 and CD66 
(Figure 4.1).  
10 µg/ml 
*Random oligonucleotide = unrelated DNA aptamer 
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To optimize the sandwich ELONA, 96-well microtitre plates (Corning, Adcock Ingram) 
were coated with 50 µl of 1 µg/ml CD119 and CD66, respectively. The antibodies were 
diluted in 10 mM NaHCO3 coating buffer (pH 8.5) and the plates incubated overnight at 
4°C. The next day, the plates were washed 3 with 100 µl TBS and blocked with 150 µl 
10% blocking buffer (fat-free milk re-suspended in TBS) then incubated for 1 h at 4°C. 
The plates were washed again with 3 with 100 µl TBS and blotted dry on paper towel 
after the final wash. IFN-γ protein was diluted in 10 mM NaHCO3 buffer (pH 8.5) and 
incubated at room temperature for 2 h. Yet again, the plates were washed 3 with 100 µl 
TBS and blotted dry on paper towel after the final wash. Aptamers were prepared at 150 
nM in 1 HMCKN buffer as described in Chapter 2, Section 2.2.3, and 50 µl pipetted 
into each well. Plates were incubated at room temperature for 2 h and subsequently 
washed 3 with 1 TBS. A 50 µl of streptavidin HRP was added to each well and 
incubated for 2 h at 37°C. Plates were washed 3 with TBS and blotted dry before 
adding 50 µl of chromogenic substrate to each well. Once the reaction turned from clear 
to blue it was stopped using 2M sulphuric acid, which subsequently turned the reaction 
from blue to yellow. The plates were immediately read at 450 nm on a microtitre plate 
reader. To disregard/rule-out non-specific binding an antibody-aptamer negative control 
was included (as blank) where no IFN-γ was present. This control was used to normalise 
the data and also test how the binding between the antibody and aptamer would bind in 
absence of IFN-γ. An antibody-antibody control was included as a positive control in 
this assay. For purposes of consistency, each experiment (for both CD119 and CD66) 
was further repeated by an independent researcher (Dr Philippa Randall, University of 
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Figure 4.1: Detection of IFN-γ by antibody-aptamer sandwich assay. 
Antibodies (CD119 and CD66) were diluted in 10 mM NaHCO3 buffer to 1 µg/ml and used to coat wells 
of a microtitre plate. IFN-γ was added at 10 µg/ml and subsequently 150 nM refolded biotinylated 
aptamer. A streptavidin-HRP enzyme was introduced, followed by addition of TMB substrate. The 
reaction was stopped by using 2 M sulphuric acid before being read on a plate reader at 450 nm. Well on 
the left (Binding aptamer) shows a positive reaction, where an aptamer bound to IFN-γ and well on the 
right (Non-binding aptamer) shows a negative reaction, where no binding was observed.  
 
4.2.3 Determining whether aptamer refolding alters binding 
Aptamers are predominantly unstructured in solution and only fold into distinct 
structures upon binding their targets (Hermann and Patel, 2000). Traditionally, aptamers 
are unfolded prior to being used by heat denaturation and rapid cooling. This is 
performed in order to ensure that the aptamer is unstructured and thus able to form 
distinct secondary structures upon binding target. On the contrary, when developing a 
POC test such as a biosensor that incorporates aptamers (often referred to as an 
“aptasensor”) this step needs to be excluded as it might not be feasible for the intended 
application. Therefore, to validate if aptamer refolding will be necessary for the IFN-γ 
aptamers, two batches of aptamers were prepared. Both batches were thawed; one was 
prepared by denaturing at 95°C for 3 min, cooled on ice for 5 min and brought to room 
99 
Chapter 4: Determinations of specificity of the aptamers to IFN-, truncation and characterization of 
derivatives of aptamer A1 
 
temperature. The other batch was used as is (in native state). Both batches were tested 
using an ELONA as previously described in Chapter 2, Section 2.2.3. 
4.2.4 Structural characterisation of full length aptamer A1 
4.2.4.1. Truncation of aptamer A1 
In-silico truncations of aptamer A1 were performed using Mfold 
http://www.bioinfo.rpi.edu/applications/mfold . The strategy used to perform the 
truncations was that bases were removed from the 3-end of the sequence. The guanine 
bases responsible for forming the G-quadruplex were closer to the 5-end. Therefore, 
since this aptamer has the ability to form a G-quadruplex, the bases responsible for 
forming the structure were not disrupted. The same parameters used to fold the 
secondary structures were used when folding the truncated derivatives and the predicted 
binding site. Furthermore, in order to confirm that the G-quadrupplex structures were 
not disturbed, truncated derivatives were yet again analysed for putative G-quadruplex 
formation using QGRS Mapper, http://bioinformatics.ramapo.edu/QGRS/ (Kikin et al., 
2006).  
 
4.2.4.2. Validation of synthesized apatamer A1 truncated derivatives 
The truncated derivatives synthesised on a 200 nM scale and biotin-labelled at the 5-end 
were ordered from Biosearch Technologies (CA, USA). The lyophilized derivatives 
were then re-suspended in ultra-pure distilled water and approximately 100 nM 
electrophoresed on a 12% native PAGE. The full-length aptamer was included as a 
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4.2.4.3. Measuring binding of the truncated derivatives vs. full-length 
Following validation of the truncated derivatives’ size on a gel, their binding efficiencies 
were determined using an ELONA as previously described (Chapter 2, Section 2.2.3). 
Each aptamer at 150 nM was prepared by refolding as previously described prior to use. 
The reason for using 150 nM was to ensure complete saturation as lower concentrations 
resulted in decreased binding affinity to IFN-γ (Chapter 3, Section 3.3.4.2). Two 
negative controls, Malaria aptamer (27mer) and HIV aptamer (15mer) were included 
and were donated by Professor Kevin Plaxco (Department of Biochemistry and 
Chemistry, University of California, Santa Barbara).  
 
4.2.4.4. Binding kinetics of truncated derivatives of aptamer A1 using ELONA  
Binding kinetics of truncated derivatives of aptamer A1 were determined using ELONA 
as previously described in Chapter 3, Section 3.2.2.3.  
 
4.2.4.5. Binding kinetics of truncated derivatives of aptamer A1 using SPR   
In addition, truncated derivative of aptamer A1 were characterised by determining the 
binding kinetic parameters using SPR as previously described in Chapter 3.  
 
4.2.5 Statistical Analyses 
Data were analysed as described in Chapter 3, Section 3.2.4. A paired two-tailed t-test 
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4.3 RESULTS 
4.3.1 Validation of specificity of aptamers to IFN-γ 
To test whether the ssDNA aptamers isolated against IFN-γ were specific, I validated 
them against mycobacterial and non-mycobacterial molecules (listed in Table 4.1). The 
aptamers only bound significantly (p≤0.001) to IFN-γ and not to any other tested 
molecules, including those frequently found within the pleural fluid such as albumin and 






























































Figure 4.2: Specificity of aptamers to IFN-γ in relation to mycobacterial and non-
mycobacterial molecules. 
Each aptamer was tested at 150 nM. All the molecules tested were at a final concentration of 10 µg/ml. The 
mycobacterial molecules tested were; lipoarabinomannan (LAM), interleukin 4 (IL-4), and purified protein derivative 
(PPD). Some of the proteins found in abundance in the pleural fluid and tested included: albumin and glucose. Casein, 
an abundant protein found in milk (hereto used as blocking buffer) was also included as a control to rule out the 
possibility of the protein blocking all the available binding sites. Bovine serum albumin (BSA) was also included as a 
negative control. Data represent two independent experiments (n=2) each done in triplicate. Error bars denote a mean 
± SE and *** denotes p≤0.001. 
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4.3.2 Aptamer-Antibody sandwich ELONA 
Aptamers are useful in sandwich assays as aptamer-antibody pairs (Drolet et al., 1996, 
Engvall and Perlmann, 1971). Two anti-IFN-γ monoclonal antibodies, CD119 and 
CD66, were tested in sandwich ELONA with each aptamer in the presence of IFN-γ. 
The OD450 of each of the antibody-aptamer pairs was less than that of the aptamer-only 
control (Figure 4.3). For aptamer A1, the aptamer-only control had an OD of 1.3062 vs. 
ODs of 0.3452 (p≤0.001) and 0.4766 (p≤0.001) for anti-IFN-γ antibodies CD119 and 
CD66, respectively (Figure 4.3A). Also, aptamers paired with CD66 generally had 
higher binding than those paired to CD119. For example, aptamer H12 had an OD of 
0.802 when paired to CD66 and an OD of 0.463 when paired to CD119 (p≤0.001) 
(Figure 4.3F). Similarly, aptamer B4 had an OD of 0.5168 when paired with CD66 and 
an OD of 0.1888 when paired with CD119 (p≤0.001) (Figure 4.3D). 
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Figure 4.3: An aptamer only (Direct) ELONA vs. aptamer-antibody sandwich ELONA. 
 
Two monoclonal anti- IFN-γ antibodies, CD119 and CD66 were tested for binding IFN-γ in the presence of the 
aptamer. On separate microtitre plates, wells were coated with 1 µg/ml of either antibody, CD119 or CD66. The IFN-γ 
and aptamer were then introduced and the binding affinity compared to direct testing of IFN-γ in absence of antibody 
(direct ELONA). On each plate, each molecule (aptamer or antibody) was tested alone, to rule out contamination. 
Also added was the aptamer + antibody control (in absence of IFN-γ) for each aptamer. A paired two-tailed t-test was 
used to determine significance (*p≤0.05, **p≤0.01, ***p≤0.001) between the aptamer only assay and the aptamer-
antibody sandwich assay. Data are for two independent experiments repeats (n=2) each done in triplicate. Results are 
presented as mean ± SE. The error bars represented the difference in the arithmetic means of optical densities at 450 
nm measured in triplicate. 
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4.3.3 Aptamer refolding does not alter binding affinity 
Aptamers are usually refolded by denaturation at high temperatures before being used. 
This is done to ensure that they are linear and thus will be able to assume the active 
secondary structure upon binding with target. To test whether the refolding step was 
necessary for IFN-γ aptamers, we tested two batches of each aptamers which were 
prepared differently. After thawing, one batch was denatured to 95°C followed by 
cooling (refolded), and the other batch was used directly (native). Aptamer A1 showed a 
significant (p≤0.01) difference in binding when refolded compared to when in a native 
state at OD450, 0.497 vs. 0.828 (Figure 4.4). All other aptamers (A2, A9, B2, B4 and 
H12) showed no significant differences when tested in the two different states. Aptamer 
A1 illustrated increased binding affinity when it was not refolded, which is ideal for 









































Figure 4.4: Aptamer refolding vs. native state. 
 
Each aptamer was prepared differently and the binding affinity assessed. One batch was denatured at 
95°C, rapidly frozen and cooled to room temperature, while the other batch was only thawed and used 
directly. The two batches were thus tested using an ELONA and their binding affinities compared. A 
paired two-tailed t-test was used to asses significance between the refolded and native aptamers, where 
p≤0.05 was denoted by *. The error bars represented the difference in the arithmetic means of optical 
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4.3.4 Structural characterisation of aptamer A1 
4.3.4.1. Truncation of aptamer A1 
Aptamer A1 was truncated and optimized for future incorporation into the biosensor for 
EPTB, due to its affinity to IFN-γ, the ability to bind IFN-γ significantly better in its 
native form and propensity to form G-quadruplexes. It was truncated into three 
derivatives, where the one showing the best efficiency was chosen for further 
characterisation. The full-length (90mer) was truncated to 49mer, 36mer and 29mer 
derivatives, respectively (Figure 4.5). When the derivatives were compared to the 
90mer, they all shared a common 25nt double stem hairpin loop (Figure 4.5). 
Additionally, the 49mer and 36mer had two secondary structure predictions hereto 
referred to as truncation 1 (T1) and truncation 2 (T2), with minimum free energies of 
T1=Δ-1.93; T2=Δ-5.08 and T1=Δ-1.93; T2=Δ-2.87, respectively. The 29mer only had 
one predicted structure, with a minimum free energy of Δ-2.87. The common double 
stem hairpin loop was suspected to be the predicted binding site of the aptamer. Also, 
this double stem hairpin loop was seen on at least one structure (T1) of the two 
predictions for truncated derivatives 49mer and 36mer. Furthermore, the minimum free 
energies for the structures (with the double stem hairpin loop) seemed to increase as the 
truncated derivative became shorter, from 90mer being Δ-5.59 then to Δ-5.08 for 49mer, 
then to Δ-2.87 for both 36mer and 29mer. 
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Figure 4.5: Structures and minimum free energies of final truncate derivatives showing preservation of the stable hairpin loop after truncation.   
Aptamer A1 was truncated to yield 49mer, 36mer, and 29mer derivatives. The double hairpin loop responsible for binding is highlighted in a blue dashed box, and was found to be 
present on all the derivatives. The minimum free energies, which gave an indication of the stability of the structure, were found to be 49mer: T1=Δ-1.93; T2=Δ-5.08, 36mer: T1=Δ-
1.93; T2=Δ-2.87, 29mer: Δ-2.87, with the 90mer being Δ-5.59. The guanine bases which enabled all truncated derivatives to still have the ability to form a G-quadruplex structure 
are underlined (shown on each sequence). The aptamer sequences are shown on flanking sides of the 90mer sequence in blue. 
107 
Chapter 4: Determinations of specificity of the aptamers to IFN-, truncation and characterization of 
derivatives of aptamer A1 
 
4.3.4.2. Confirmation of truncated derivatives forming G-quadruplexes 
After truncating aptamer A1 to 49mer, 36mer and 29mer derivatives, they were analysed 
for putative G-quadruplex formation. As expected, all truncated derivatives could form a 
G-quadruplex structure (Table 4.2). The positions of the bases (GG doublets) 
responsible for forming the G-quadruplex was the same, from position 2and position 23 
of the full length (90mer) parental aptamer. The position of the bases for the 90mer was 
different because the sequence was longer; it included the primers. The length of the 
sequence forming the G-quadruplex, for the truncated derivatives and for the 90mer, was 
found to be the same; containing 22 bases with the same   G-score. The G-score of the 
derivatives and the 90mer was found to be the same at 17, which is expected since the 
same bases were responsible for the formation of the G-quadruplex for all derivatives. 
 























36mer 2 22 GGCGAAGGCACGTGTGGGGTGG 17 5ʹCGGCGAAGGCACGTGTGGGGT
GGTCGCGTTGTGTCG-3ʹ 
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4.3.4.3. Validation of synthesised truncated derivatives of aptamer A1 
All the aptamers were the expected sizes, which was between 20 and 100 bp (Figure 
4.6). The 90mer appeared as a smear and this was an indication of the multiple possible 
conformations that it could undergo (Figure 4.6). The higher band indicating the 
formation of a G-quadruplex is supposed to be 4x the number of nucleotides in the 
sequence. It was noted that the higher band indicative in lane 2 was a contaminant 
(which was about 90 nucleotides long (equivalent to the 90mer in lane 1), therefore 
suggestive of a spill-over from lane 1 during aptamer loading onto gel).  
 
 
Figure 4.6: A1 truncated derivatives were validated on a 12% non-denaturing PAGE to determine 
their sizes and topologies. 
Truncations of aptamer A1: 49mer, 36mer, and 29mer, were run on a 12% non-denaturing PAGE to 
determine their sizes, and was compared to the full length 90mer. The lanes were loaded from the largest 
to the smallest aptamer (lanes 1-4). Lane M: Marker; Lanes 1-4: 90mer, 49mer, 36mer: and 29mer, 
respectively. The higher bands in lanes 1, 3 and 4 (indicated by blue arrows), are an indication of the 
aptamer forming a G-quadruplex and their sizes are denoted in blue. A double-stranded DNA marker was 
used and therefore the sizes of the aptamers are not expected to be accurately displayed on this gel. The 
motilities of the aptamers however, were about the expected size (between 20 and 100 bp). A faint band 
seen in lane 2 (denoted with a blue circle) is indicative of a contaminant. 
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4.3.4.4. Measuring binding efficiencies of full-length vs. truncated derivatives 
The binding affinity of the 90mer was compared to the truncated derivatives, 49mer, 
36mer and 29mer using an ELONA (Figure 4.7). The binding of the 49mer was 
significantly reduced at OD450 (OD of 49mer = 0.403 vs. 90mer=0.651 (p≤0.01)) 
compared to 90mer. No difference in binding was observed for 36mer and 29mer 
compared to the 90mer (Figure 4.7). These data suggested that the 36mer and 29mer 
derivatives bound IFN-γ comparatively similar to the 90mer. Two aptamer truncated 
derivatives which are unrelated to TB were used as negative controls (27mer malaria 
aptamer and a 15mer HIV aptamer) and none of them significantly bound IFN-γ. Since 
the shortest aptamer that retains functionality is ideal for use in most downstream 







































































































Figure 4.7:  Binding of the A1 truncated derivatives compared to the full length parental aptamer 
and controls. 
A paired two-tailed t-test was used to assess significance, ** denotes p≤0.01. The experiment was 
performed in triplicate in two independent experiments (n=2). The error bars represented the difference in 
the arithmetic means. 
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4.3.4.5. Binding capacity of selected truncated derivatives 
The binding capacity of the full length aptamer A1 was investigated using a 
concentration of 10 µg/ml of IFN-γ. Aptamer A1 was able to significantly bind 10 µg/ml 
IFN-γ at 18.75 nM. It was therefore necessary to test if these results will be reproduced 
with truncated derivatives. All the truncated derivatives were assessed and the 90mer 
included as a positive control (Figure 4.8). Only truncated 49mer derivative could 
significantly bind IFN-γ at 18.75 nM (Figure 4.8)  
 
Figure 4.8: Binding of truncated derivatives of aptamer A1 to constant IFN-γ concentration of 10 
µg/ml. 
Aptamer A1 truncated derivatives were tested in a 2-fold serial dilution at 150 nM, 75 nM, 37.5 nM and 18.75 nM, 
using a constant concentration of IFN-γ of 10 µg/ml. Following the addition of the aptamers at different 
concentrations, the rest of the parameters were kept constant throughout the assay. The binding of aptamers from 75-
18.75 nM was compared to the binding of each aptamer at 150 nM using 1-way ANOVA with Bonferroni’s post-test 
where significant differences were denoted by *=p≤0.05, **=p≤0.01 and ***=p≤0.001. Data are for two independent 
experiments (n=2) each done in triplicate. Error bars represent mean ± SE. 
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4.3.4.6. Binding kinetics of truncated derivative: A1-29mer 
In addition to characterising the aptamer A1-29mer for its possible incorporation into an 
application such as a biosensor, its kinetic parameters including association constant rate 
(Ka), dissociation constant rate (Kd) and equilibrium dissociation constant (KD) were 
determined using SPR (Figure 4.9). A large increase in the association constant (Ka) of 
the 29mer compared to the 90mer, from 3.75E+4 to 1.29E+7 was seen (Figure 4.9). 
Additionally, truncated derivative 29mer dissociated from IFN-γ with a Kd of 1.32E-3, 
which was an increase from 2.02E-4 calculated for the 90mer (Table 4.2). The 
calculated KD was found to be 1.02E-10 for the 29mer compared to 5.39E-9 for the 
90mer (Figure 4.9 and Table 4.2). This data supported the hypothesis that shorter 
derivatives of an aptamer can increase the binding affinity and in return produce tighter 
complexes between the molecules (aptamer) and the target (IFN-γ).  
 

































Figure 4.9: Binding kinetics of A1-29mer Biacore. 
The equilibrium dissociation constant (KD) of the 29mer truncated derivative was determined using SPR 
technology. Recombinant IFN-γ was immobilised on a CM5 chip and each aptamer was exposed to the 
immobilised IFN-γ at varying concentration, ranging from 0.13 nM to 1000 nM. The aptamer 
concentration series is shown on the top right corner of each graph and the KD is shown at the bottom right 
corner. The aptamers and the IFN-γ were allowed 7 min contact time before dissociation. To calculate and 
determine the equilibrium dissociation constant using the association and dissociation constant rates, a 1:1 
Langmuir model was assumed using the BIAevaluation v4.1 software. The assay was performed in 
triplicate and the average KD determined. The KD was calculated by assuming a 1:1 Langmuir model using 
the BIAevaluation software package.  
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4.4 DISCUSSION 
In this chapter, I further characterised the six aptamers and truncated derivatives of 
aptamer A1. The key findings were: (i) the aptamers were specific to IFN-γ (ii) aptamer-
antibody ELONAs had less binding affinity compared to direct (aptamer only) 
ELONAs; (iii) truncated A1-derivatives had similar free energies and generally kept 
structural features important for binding; (iv) the truncated A1-29mer derivatives 
showed increased performance and stability compared to the full length parental 
molecule.  
 
The most important prerequisites of a good clinical POC diagnostic test are high 
sensitivity, specificity and rapidity. Aptamers can have specificities and affinities that 
are comparable to monoclonal antibodies, and in some cases are superior (McKeague et 
al., 2010, Jayasena, 1999). IFN-γ aptamers raised in this study were found to be highly 
specific. This was similar to findings reported for other aptamers isolated  against M. 
Tuberculosis cell component lipoarabinomannan (LAM) (Pan et al., 2014) and other 
targets such as human influenza-B virus, Shigella dysenteriae, Leshmania infantum and 
Vibrio alginolyticus (Gopinath et al., 2006a, Tang et al., 2013, Duan et al., 2013, Martín 
et al., 2013).  
 
None of the IFN-γ aptamers described in this study bound any of the mycobacterial and 
non-mycobacterial molecules they were tested against. Thus, the aptamers did not 
significantly bind mycobacterial molecules such as PPD and LAM and human markers 
made in response to mycobacterial infection such as IL-4. Interestingly, the aptamers 
also did not bind molecules known to be present in abundance in the pleural fluid such 
as albumin and glucose. Although previous work by others has described isolation of 
aptamers against  IFN-γ; specificity of the aptamers was not determined 
(Balasubramanian et al., 1998). However, a recent study demonstrated good specificity 
of a DNA aptamer isolated against IFN-γ for its intracellular measurement in an 
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immunoassay (Cao et al., 2014). The aptamer was tested against albumin, since it is a 
protein well known to be abundant in blood (Cao et al., 2014). Additionally, they used 
Balasubramanian’s aptamer as a control, and that showed binding to albumin, suggesting 
that it lacked specificity (Cao et al., 2014, Balasubramanian et al., 1998). The results of 
this study therefore suggest that the aptamers are unlikely to yield false positive results 
due to non-specific binding. Although not all molecules contained in the pleural fluid 
were tested, the ability of the aptamers to not cross-react with any of the highly abundant 
constituents was an encouraging finding. 
 
To address the suboptimal IFN-γ sensitivity reported in Chapter 3, an aptamer-antibody 
sandwich ELONA was optimised to increase performance. Studies have shown 
sandwich assays to have the ability to exceed the sensitivity and specificity compared to 
direct assays (Drolet et al., 1996, Grebenchtchikov et al., 2004). As an example, Drolet 
and co-workers (1996) performed a sandwich ELONA (using an aptamer and antibody) 
to detect and quantitate VEGF isoform in serum samples and compared it to an ELISA, 
which it outperformed yielding a sensitivity of 25pg/ml. In addition, the ELONA had 
higher OD readings compared to the ELISA in twelve of the 21 (57%) serum samples 
tested. In a similar study, Shiratori and colleagues reported binding affinities 10-fold 
higher in a sandwich ELONA compared to a direct assay. Additionally, the direct assay 
needed a 100-fold more concentration of the virus, to generate a signal similar to the 
indirect assay (Shiratori et al., 2014). The aptamer-antibody sandwich assay described in 
this study was, however, outperformed by the direct (aptamer-only) ELONA. The direct 
ELONA also yielded higher OD values compared to the aptamer-antibody sandwich 
assay. Binding in the direct format was almost twice that of the sandwich assay (e.g. for 
aptamers B2 and H12), which was similar to findings reported by others (Shiratori et al., 
2014). These findings therefore suggested that the direct assay was more sensitive. Two 
possibilities could be responsible for this phenomenon. Either there were no epitopes 
available for both the aptamer and the antibody to bind. For instance, it is obvious that 
both molecules need to bind the target on two different epitopes in order for the assay to 
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be a success. Therefore, the target protein needs to be mapped using technologies like 
nuclear magnetic resonance (NMR) or X-ray crystallography to ensure that both 
molecules can simultaneously bind. In fact, using two aptamers could actually be a 
solution. Balogh and co-workers (2010) developed a double-oligonucleotide sandwich 
(DOS) ELONA for detecting protein in complex virus matrices, which outperformed 
commercial double-antibody sandwich assay (Balogh et al., 2010).  The same approach 
was reported by Shiratori (Shiratori et al., 2014), and both groups demonstrated 
improved sensitivities. Alternatively, site directed SELEX can be performed from the 
beginning, in order to isolate aptamers targeted at certain epitopes (Kulbachinskiy, 
2007).  
 
On the other hand, the aptamers could assume a different structure in presence of the 
antibody. Interestingly, my data suggested that the binding of the aptamers to IFN-γ was 
not affected by a refolding step except for aptamer A1. This meant that the binding of 
the aptamers was the same irrespective of whether they were denatured or not. This 
could be an indication that the aptamers only self-assembled into specific conformations 
upon binding the target and were not dependent on a denaturation step. Furthermore, the 
phenomena seen for aptamer A1 could be suggesting that the “unstructured” aptamer in 
solution can linearize and bind without being denatured. Rotherham et al reported the 
same results for ESAT6:CFP10 aptamers and this bodes well for the future development 
of POC clinical diagnostics (Rotherham et al., 2012).  
 
In order to understand the binding mechanisms of aptamers, knowledge of the structure 
of the aptamer and the predicted binding site are important. Furthermore, not all 
nucleotide bases of an aptamer are essential for binding. In fact,, structural analysis 
showed that aptamers can retain their functionality even when the essential bases are 
removed, provided the structure of the necessary bases does not change (Jayasena, 
1999).  Truncations are usually performed to remove non-essential nucleotides of an 
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aptamer sequence, thus increasing sensitivity and specificity and reducing production 
costs during chemical synthesis. In addition, truncated derivatives are structurally 
suitable and ideal for incorporations into biosensing platforms.  
 
In this study aptamer A1 was truncated because it had a KD in the low nanomolar range 
(5.39E-9), it bound significantly better to IFN-γ, and it had the ability to form a G-
quadruplex due to its guanine-rich sequence. This was supported by the evidence 
showing the ability of full length aptamer A1 to encompass a range of multiple 
conformations (DNA sizes ~90 nucleotides and ~20 nucleotides) on a non-denaturing 
PAGE (Figure 4.6). Furthermore, the truncated derivatives were also able to form G-
quadruplexes which was apparent on this type of gel, thus highlighting their stability. G-
quadruplexes can appear as monomeric or multimeric form (Shum and Tanner, 2008). 
The migration of truncated derivatives 36mer and 29mer was an indication of their 
multimeric forms. The higher band seen in lanes 1, 3 and 4 is an indication of this. 
Therefore, the total number of nucleotides of each truncated derivative was multiplied 
by four in order to accurately identify the G-quadruplex. As such, the expected sizes 
were 360mer (90x4), 144mer (36x4) and 116mer (29x4) for the 90, 36 and 29mer, 
respectively (Figure 4.6). An interesting observation made was that the 49mer 
derivative was different in topology from other derivatives and the full length aptamer 
(based on the different mobilities). The 49mer was monomeric as it ran as a single band, 
which has been seen in previous studies (Hamilton and Germann, 2011, Shum and 
Tanner, 2008). Also noted was that the 49mer derivative had reduced binding compared 
to the full length aptamer and other derivatives (36mer and 29mer) (Figure 4.7). The 
loss in sensitivity could be attributed to the fact it forms a monomeric G-quadruplex, as 
seen on the non-denaturing PAGE. The topologies of the truncated derivatives can 
further be confirmed by circular dichroism (CD) studies, which is a widely used 
technique for this purpose. 
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Although the binding of the 49mer was reduced compared to the 90mer, the binding 
affinity of the 36mer and 29mer was similar. Of interest though, was the fact that all 
truncated derivatives retained the common 25nt double stem hairpin loop, even though 
the binding affinities differed. Due to the high affinity for IFN-γ that the 29mer had, it 
was selected to be further characterised for its possible future incorporation into a 
biosensor. SPR was used to determine the KD of the truncated aptamer. Indeed, a large 
increase in the Ka was seen, signifying a very quick “on-rate”. In terms of POC tests, 
this characteristic will be valuable as the process will be a timed reaction. This means 
that the aptamer-IFN-γ complex will be able to form in less than 10 min. In addition, an 
improved KD for the 29mer was also observed. It is possible that this KD could be 
inaccurate as the SPR curves did not clearly show the “off-rate” (Figure 4.9) compared 
to those seen for the full length aptamer A1 (Figure 3.8).  It looked like the aptamer-
IFN-γ complex was not coming “off”/separating. The size of the aptamer could have 
contributed to its instability when used in this type of assay. Another group has reported 
similar findings where truncated derivatives had increased KD (20 nM to 1.4 nM) 
compared to their full length counterparts (Nonaka et al., 2010). This further supports 
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4.5 CONCLUSION 
I have demonstrated that IFN-γ aptamers are specific and have no cross-reactivity with 
other molecules common in the pleural fluid like albumin and glucose. Anti-IFN-γ 
monoclonal antibodies when used in conjunction with aptamers did not improve 
sensitivity, likely due to shared epitopes. Furthermore, I demonstrated the efficiency of a 
truncated derivative, A1-29mer, which performed equally well as the 90mer. Moreover, 
I showed in silico that truncated derivatives retained their G-quadruplex structures, 
which the full-length version had. Taken together, these data could be used as a basis for 
the future development of these aptamers in diagnostic applications for EPTB. 
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5.1 SUMMARY OF FINDINGS 
 
This study described the generation and characterisation of aptamers for the detection of 
IFN-γ (a clinically important biomarker for the diagnosis of extra-pulmonary TB) using 
SELEX technology. To date, there are limited diagnostics for pleural TB: i) ADA 
colorimetric assay; ii) culture; and iii) smear microscopy. These tests, however, have 
low sensitivity and consequently result in false negatives thereby missing many 
individuals with EPTB. Even the newest NAAT technology like the GeneXpert has sub-
optimal sensitivity of only ~20% in EPTB cases (Meldau et al., 2014, Friedrich et al., 
2011, Moure et al., 2012). This therefore warranted the need to develop a POC test with 
high sensitivity and specificity. 
 
Eight iterative rounds of selection were performed where a pool recovered from the sixth 
round (which had the highest recovery) was cloned and sequenced. Sixty aptamer 
candidates were identified, which shared sequence homology and a consensus sequence 
was determined. Forty five candidate aptamers specifically bound IFN-γ. Six aptamers 
were randomly selected for further characterisation. 
 
The six selected aptamers bound IFN-γ with high affinity and specificity. Their 
structural characteristics comprised of long hairpin stem loops, which contributed to 
their increased affinity. The stability of the aptamers (aptamers A1 and B4) was 
enhanced by their ability to form G-quadruplex structures, which is a feature of high 
performance aptamers commonly used in biosensors and microfluidic devices (Song et 
al., 2008, Hong et al., 2012, O'Sullivan, 2002, Willner and Zayats, 2007, Zhou et al., 
2010, Xu et al., 2009). Of importance was the ability of all aptamers to discriminate 
against other mycobacterial molecules and non-mycobacterial molecules including those 
contained in the pleural fluid. This finding showed minimal cross reactivity of proteins 
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within the pleural fluid, although it could not be established if the pH and salt content 
will potentially affect the binding of aptamers in the pleural fluid sample (Banerjee and 
Nilsen-Hamilton, 2013).  
 
This study confirmed that the aptamers have high affinity for their targets in the low 
nanomolar range, which is similar to that of antibodies. Their size and ability to form 
different structures, however, can result in an even lower dissociation constant 
(picomolar range). Aptamers A9 and H12 bound IFN-γ in the picomolar range at 206 
pM and 390 pM, respectively. The LOD was found to be 10 µg/ml for all the six 
aptamers, which is similar to other studies that have created aptamers to Vibrio 
alginolyticus and Leishmania infantum (Tang et al., 2014, Martín et al., 2013). IFN-γ is, 
however, found in picogram concentrations in pleural fluid. Recent work using an “in-
house” ELISA-like assay determined the biological range of IFNy in individuals with 
pleural TB to be as low as 110 pg/ml (Meldau et al., 2014). Therefore the inability of the 
aptamers to detect IFN-γ in this biological range could pose a challenge as they have 
high specificity but reduced sensitivity. In view of this finding, I paired the aptamers 
with an anti-IFN-γ antibody with the expectation of achieving an improved LOD since 
sandwich assays have been shown to have high sensitivity (Drolet et al., 1996, 
Grebenchtchikov et al., 2004). The data showed no improvement in signal when the 
sandwich assay (aptamer-antibody) was compared to the performance of the aptamer 
only assay. This could mean two things: (i) Either the aptamer and antibody competed 
for the same epitope on IFN-γ, hence the decreased signal, or (ii) only the antibody is 
binding. These findings provide evidence of the potential of aptamers to be used in 
diagnostic platforms. 
 
To validate if truncations could improve the binding affinity to IFN-γ, one aptamer was 
selected. Aptamer H12 was a likely candidate as it had the qualities one would selected 
for in terms of specificity, affinity and stability. However, this aptamer was not a 
putative G-quadruplex forming aptamer, which is important for devices based on 
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biosensor or microfluidic technologies. The lack of this characteristic favoured 
truncation of aptamer A1, whose performance was within the acceptable standards. The 
truncated derivatives were tested and their bindings favourably compared to the full 
length aptamer. Thus, the binding affinity of the truncated derivatives was not superior 
to the full length, but rather remained the same, which is in agreement with other reports 
(Rockey et al., 2011). Binding kinetics of the truncated derivative A1-29mer revealed an 
improved KD further supporting the hypothesis that non-essential bases of aptamers can 
be removed without compromising  functionality (Baouendi et al., 2012).  
 
In this study, a novel truncated DNA aptamers that bound IFN-γ with high affinity in the 
low nanomolar range was discovered. This is supported by the fact that all truncated 
derivatives retained the 25nt double stem loop, which is hypothesised to be the actual 
binding site of the aptamer. Furthermore, all truncated derivatives could still form G-
quadruplex structures, which could further be characterised by CD, X-ray 
crystallography, and/or NMR, in order to understand further their topologies prior to 
using them in downstream diagnostic applications. 
 
5.2 IMPLICATIONS OF THIS STUDY  
Since the announcement of the pipeline of developing novel technologies to curb the TB 
epidemic by the World Health Organisation, great strides have been made in the field. 
About 25% of the TB population has EPTB and this prevalence escalates to almost 50% 
in HIV-AIDS endemic populations (Sharma and Mohan, 2004). Although many 
successful advances have been made in the diagnosis of PTB since the development of 
the GeneXpert, it has proved unhelpful in the diagnosis of EPTB. Recent work including 
findings from our group and others showed that using GeneXpert to diagnose EPTB had 
low sensitivity (~20%) (Meldau et al., 2014, Friedrich et al., 2011, Moure et al., 2012, 
Porcel et al., 2013). Even when using other specimens for EPTB i.e. cerebrospinal fluid 
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(CSF) and urine for diagnosis with the same technology, the sensitivity was still sub-
optimal (Hillemann et al., 2011, Patel et al., 2013).  
 
Since the discovery of IFN-γ as a biomarker for EPTB diagnosis, there is still a lack of 
POC tests on the market. A University of Cape Town (UCT) spin-off company, Antrum 
Biotech Inc. has developed a diagnostic test for pleural TB (Meldau et al., 2014). This is 
an antibody-based assay. The drawbacks associated with these antibodies, however, 
have driven researchers to look elsewhere for molecules that will overcome the 
challenges faced by antibodies or maybe even surpass them by performance. In 
particular more sensitive and rapid assays are required to detect IFN-γ for incorporation 
into POC assays e.g. lateral flow assays. The aptamer technology has thus been the most 
recently explored avenue in this regard i.e. likely to have better sensitivity but more 
importantly short binding times of minutes compared to hours for ELISA thus 
shortening assay time. Hence, the current project was undertaken. 
 
It has been shown that the performance of aptamers could possibly surpass those of 
antibodies (Jayasena, 1999) in a number of assays (Kulbachinskiy, 2007) thus possibly 
creating a niche of their own in diagnostic applications. The amenability of aptamers 
makes them attractive for specific applications such as biosensors and microarrays, 
where modifications are vital. Aptamers have been shown to retain their sensitivity post 
modification. Thus, the aptamers described in this study could be incorporated into an 
aptasensor and improve their sensitivity by coupling the sensor with an electrochemical 
readout, which will enhance the signal. With the properties that aptamers come with 
including their stability, robustness and ease of manufacturing, they are set to change the 
field of diagnostics. To develop a diagnostic kit, or any other POC device, good 
sensitivity and specificity cannot be compromised upon. Aptamers have this ability. 
Even though desired sensitivity levels are sometimes a challenge to achieve, the signal 
can always be amplified using technologies such as electrochemistry, or gold 
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nanoparticles. PCR could alternatively be a simple method to use. Other potential 
advantages include reducing assay time thus reducing overall turnaround time.  
 
5.3 LIMITATIONS OF THIS STUDY 
I. Overall limit of detection 
The LOD for IFN-γ using the aptamers was 10 µg/ml.  ELISA tests used to 
detect IFN-γ in pleural fluid samples, however, have sensitivity levels in the 
picomolar range. The lower than expected sensitivity of the aptamers could 
possibly be attributed to the artefacts of the SELEX protocol, such as PCR bias 
and the starting concentration of the IFN-γ or less stringent conditions when 
performing the SELEX.  
 
PCR amplification bias could have played a role in the loss of identifying high 
affinity binding aptamers, by preferentially enriching sequences which were 
more abundant but with decreased affinity. The most abundant aptamers will be 
PCR amplified more efficiently and could result in the loss of other sequences. A 
way to mitigate this would be to sequence an aliquot from each recovered pool at 
every round to ensure that high-affinity binders were carried through to the next 
round. To date, these mitigating steps have not been required during a SELEX 
protocol as aptamers with high sensitivity have been produced against various 
targets e.g. cocaine aptamer, and their LOD are the same order of magnitude as 
that reported here. Nevertheless, despite this suboptimal LOD, this is the first 
study to isolate IFN-γ aptamers for the diagnosis of EPTB. None of the two IFN-
γ aptamers described in literature were assessed for this (Balasubramanian et al., 
1998, Cao et al., 2014, Lee et al., 1996).  
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Another possible contribution to the suboptimal LOD was that aptamers should 
have been isolated against IFN-γ in the biological range (picogram levels). This 
could have also been introduced as a stringency method (decreased concentration 
at later rounds) during the selection process. Due to the large variations in the 
concentration of IFN-γ in biological samples (Meldau et al., 2014), and the 
information obtained from this project, future studies can be designed to select 
aptamers using picomolar concentrations of IFN-γ. 
 
II. Only a subset of aptamer clones were sequenced and not the entire final 
recovered pool 
Due to resources available at the time of this study, after the SELEX reached a 
plateau the final recovered pool was cloned and only 96 randomly picked 
colonies were sequenced. Additionally, some sequences were eliminated for 
various reasons discussed in Chapter 2. In future studies, to overcome this 
limitation, one would design the study so that high-throughput sequencing 
platforms like Illumina (Schütze et al., 2011, Cho et al., 2010, Guo et al., 2014) 
would be used as they produce a significantly higher number (thousands-
millions) of reads. Nevertheless, the number of sequences screened is similar to 
other studies. For example, Cao and co-workers (2014), Ferreira and co-workers 
(2008) and Rotherham et al (2012) analysed 96, 100 and 104 clones, respectively 
(Cao et al., 2014, Ferreira et al., 2008, Rotherham et al., 2012).  
 
III. Clinical validation not done  
While a clinical validation could have strengthened the study, it should be noted 
that numerous studies on aptamers exclude a clinical validation (Ngubane et al., 
2014, Gopinath et al., 2006a, Grozio et al., 2013). A small set of clinical samples 
were tested for pleural TB. However, the sensitivity could not be determined 
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(data not shown). The experiment failed, and I hypothesised that it could have 
been for one of the following reasons: 
 The aptamer could have been unable to detect the low levels of IFN-γ in 
the pleural fluid. 
 The aptamers could have been undergoing degradation due to the 
presence of nucleases in the pleural fluid. Neither the oligonucleotide 
library used for the SELEX nor the aptamers were labelled in order to 
prevent nuclease degradation.  
 The aptamers could have adopted different conformations once in pleural 
fluid, mainly because of the Na+, K+ concentrations and pH, which could 
have been different from the buffer used during SELEX. 
Future work will hopefully address these possibilities. 
 
IV. Exclusion of structurally-related proteins for specificity testing  
It is acknowledged that a structurally-related protein to IFN-γ, such as 
interferon–alpha (IFN-α) would have added more value as a control to the 
specificity data. This is important because aptamers have been shown to be 
highly specific. Their specificity is attributed to their ability to differentiate 
between two structurally-related molecules (Eaton et al., 1995, Hermann and 
Patel, 2000). This control will be included in future specificity assays. 
 
5.4  FUTURE WORK 
The aptamers need to be tested in clinical samples in order to establish their validity. 
Negative pleural fluid samples will be spiked with known concentrations of IFN-γ.  A 
diagnostic accuracy study will then be performed using clinical samples which have 
already been collected and are currently bio-banked for this purpose, for which we have 
already received ethical approval. Furthermore, the pH and salt concentrations of the 
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pleural fluid will be determined, which will assist in optimising the conditions in the 
buffers when repeating the SELEX using a different approach. We will select new 
aptamers using recombinant IFN-γ and perform rounds of counter-selection against 
other proteins e.g. albumin, which is abundantly present in the pleural fluid. To ensure 
that the newly developed aptamers will be highly sensitive in diagnosing pleural TB, I 
will optimise for detection in the biological range (picogram levels). Firstly, I will use a 
modified library to perform the selection. The nucleotide library will be modified with 
an NH2-group to make the bases nuclease resistant (Nimjee et al., 2005b, Bruce E, 
1997).The random region size will remain unchanged (as 49mer) since longer regions 
have been shown to allow better opportunities of identifying “winning” aptamers mainly 
due to the many conformations they can adopt (Marshall and Ellington, 2000). Although 
other researchers prefer to develop short aptamers which need not to be truncated later, I 
prefer the former.  
 
The new approach will also include the monitoring of the evolution of the SEELX. 
Simply put, I will sequence (Illumina sequencing) an aliquot from each recovered pool 
of every SELEX round, and I will perform alignments and phylogenetic studies to study 
the evolution of sequences. Furthermore, binding studies to determine the dissociation 
constant using SPR (Biacore 3000) will be performed for every other SELEX round 
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5.5 CONCLUSION 
I have successfully generated aptamers that bind IFN-γ with high affinity and specificity. 
Six candidate aptamers were characterised, and while inclusion with an antibody in a 
sandwich assay did not improve binding affinity, the KD of aptamer A1 was improved 
upon truncation. This implies that it is a good candidate for possible incorporation into a 
biosensing device, especially because of its ability to form a G-quadruplex. The 
aptamers generated here are, although highly specific, are unable to detect IFN-γ in the 
biologically meaningful range. Recommendations on future work include coupling 
aptamers described in these study, such as A1 and its truncated derivatives to gold 
nanoparticles to increase their sensitivity; in tandem isolate next generation aptamers 
under more stringent conditions that mimic the physiological environment and 
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APPENDIX 2A: Methods supplementary material 
 
Table S2.1: Protocol of 17% resolving gel 
Contents for resolving gel (17%) 10 ml 
 
1.5 M Tris-HCl [Sigma], pH 8.8 (0. 1% SDS) [Sigma]  
 
2.5 ml 
Acrylamide/Bis-acrylamide (40% w/v) [Sigma] 4.25 ml 











Table S2.2: Protocol of 4% stacking gel  
Components of stacking gel (4%)      5 ml 
 




    1 ml 
Acrylamide/Bis-acrylamide (40% w/v)     500 μl  
 
Ammonium per sulfate (APS) 10% (w/v) 
 
    50 μl  
 















Table S2.3: Sequences of primers and the library that was used for the SELEX 










Table S2.4: Mutagenic PCR set-up protocol using Go-Taq kit (Promega, WI, USA) 
PCR Component 1x reaction 
 
5x Go Taq Buffer 
 
220 µl 
MgCl2 [3.5 mM] 154 µl 
dNTPs [0.2 mM] 22 µl 
SELEX Forward primer [100 µM] 5 µl 
SELEX Forward primer [100 µM] 5 µl 
Go Taq 5.5 µl 
ddH2O up to 700 µl 640.5 µl 
  
 
Table S2.5: Cycling protocol for mutagenic PCR 
Cycling 
conditions 













95 °C for 1 min 
 
Annealing 54 °C for 1 min 20 Cycles 
Extension 72 °C for 1 min:30 sec  




72 °C for 8 min 
 
1 Cycle 
Hold 4 °C Indefinitely 
   








Table S2.6: Protocol for a 12% non-denaturing polyacrylamide gel  
Gel components 10 ml 
10x TBE buffer 1 ml 
Acrylamide/Bis-acrylamide (40% w/v) [Sigma] 3 ml 
Ammonium persulfate (APS) 10% (w/v) 
[Sigma] 
100 μl 




ddH2O 4.9 ml 
 
Table S2.7: Set-up of ligation reaction 
Reagent 10 μl 
 
 
2X Ligation buffer 
 
5 μl 
pGEM-T Easy vector (50ng/ 
μl) 
1 μl 
T4 DNA Ligase 1 μl 
PCR product (100ng/ μl) 1 μl 
ddH2O (3 units) 2 μl 
 
Table S2.8: Non-mutagenic PCR protocol using Go-Taq kit (Promega. WI, USA) 
PCR Component 1x reaction 
 
5X Go Taq Buffer 
 
140 µl 
MgCl2 [1.5 mM] 42 µl 
dNTPs [0.2 mM] 22 µl 
SELEX Forward primer [1 
µM] 
7 µl 
SELEX Forward primer [1 
µM] 
7 µl 
Go Taq 3.5 µl 






Table S2.9: Cycling conditions for non-mutagenic PCR 
Cycling step Temperature and time Number of cycles 




95°C for 30 seconds 
54°C for 30 seconds 
72°C for 30 seconds 
 
20 cycles 
























APPENDIX 2B: Protocol for bulking-up of ssDNA for determining binding 
affinity by   ELONA 
 
Production of ssDNA to determine the aptamer-target binding affinities 
In order to produce DNA to use for aptamer screening, PCR reactions were prepared 
by making an emulsion of each colony. A colony was scraped using a sterile pipette 
tip and inoculated into 25 µl of distilled water using a PCR 96-well plate (Corning, 
Adcock and Ingram, South Africa). The plate was then put into a PCR machine and 
heated at 95 °C for 10 min, to burst the cells. Three millilitre PCRs were performed 
under non-mutagenic conditions (Table S2.8 and S2.9). The sufficient product 
produced allowed for sufficient ssDNA to be produced following lambda 
exonuclease digestion (as described in section 2.2.1.4). The final products (ssDNA) 
were purified using the Nucleospin PCR cleaning kit (Macherey-Nagel, Dϋren, 
Germany), as per the manufacturer’s instructions. The products were further 
analysed on a 12% non-denaturing PAGE (Table S2.6), to validate the quality, and to 
ensure that all the dsDNA was completely digested. The quantity was determined 















APPENDIX 2C: The tabular format of a multiple alignment of 36 IFNγ DNA sequences identified in the 5’-3’ direction. The 
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APPENDIX 3.1: SECONDARY STRUCTURE PREDICTIONS 

























ΔG = -5.72 
  
ΔG = -5.86 
  
ΔG = -6.25 
  








































































   
 
 
ΔG = -1.13 
  































ΔG = -1.09 
  
ΔG = -1.33 
  
ΔG = -1.55 




































ΔG = -5.72 
  
ΔG = -5.72 
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*Each aptamer was t at150 nM aptamer. All the molecules tested were at a final concentration of 10 
µg/ml. Blocking buffer (casein) and wash buffer (TBS) used in the assay were tested against the aptamer 
to rule out any possible binding. Casein, an abundant protein found in milk (hereto used as blocking 
buffer) was also included as a control to rule out the possibility of the protein blocking all the available 
binding sites. Bovine serum albumin (BSA) was also included as a negative control. The mycobacterial-
related molecules tested were; Lipoarabinomannan (LAM), Interleukin 4 (IL-4), and Purified protein 
derivative (PPD). Some of the molecules found in abundance in the pleural fluid were also tested: i.e 
Albumin and Glucose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
